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ABSTRACT OF THE DISSERTATION
Methods and Mechanisms of DNA methylation in Development and Disease
By
Maximiliaan A Schillebeeckx
Doctor of Philosophy in Biology and Biomedical Sciences
Molecular Genetics and Genomics
Washington University in St. Louis, 2014
Professor Robi D. Mitra, Chair
	
  
DNA methylation is a mechanism for long-term transcriptional regulation and is required for
normal cellular differentiation. Failure to properly establish or maintain DNA methylation patterns leads to
cell dysfunction and diseases such as cancer and neurological disorders. The goal of this thesis is to
understand the role of DNA methylation in oncological cellular transformation and in normal development.
To achieve this goal, I have developed a novel method for mapping genome-wide DNA methylation
patterns and have applied the method to gonadectomy-induced adrenocortical neoplasms and to
maturing motor neurons. The novel method, called Laser Capture Microdissected-Reduced
Representation Bisulfite Sequencing (LCM-RRBS), accurately and reproducibly profiles genome-wide
methylation of DNA extracted from microdissected fresh frozen or formalin-fixed paraffin-embedded
tissue samples. Using this method, I find that significant DNA methylation changes, associated with
attendant expression changes, occur in transformed adrenocortical cells. My work has also uncovered
significant DNA methylation configuration in maturing motor neurons associated with dramatic expression
changes. I show that demethylated regions are enriched for known neuron-specific transcription factor
binding sites and that genetic disruption of the active demethylation machinery significantly inhibits motor
neuron differentiation and maturation. Together, these experiments demonstrate that DNA methylation
plays a role in the transformation of normal cells to cancer cells and that DNA methylation is critical to
proper motor neuron formation. I conclude that aberrant DNA methylation controls gene expression in
gonadectomy-induced adrenocortical neoplasms and that neuron-specific transcription factors could
recruit demethylating enzymes to regions that lose DNA methylation in motor neurons upon maturation.

x

CHAPTER 1: INTRODUCTION

OVERVIEW
The genetic code of life is incredibly static and robust. From one cell, with two genome copies,
results a multi-cellular organism made of over 100 distinct cell types (Gilbert 2013). Each cell contains an
(almost) exact copy of that original genome present in the first cell, yet can exhibit unique cellular
morphologies and functions (Gilbert 2013; Lodish 2013). What’s more, scientists have observed that as a
fertilized egg develops into a mature embryo, daughter cells of the first, totipotent cell gradually lose the
ability to differentiate into any cell type. Indeed, as early cells differentiate toward one of three germ
layers, which specialize into different cell types, cells lose the potential to revert to a different germ layer
and become committed to the lineage. As a blastocyst develops, these intermediate progenitor cells
further differentiate to the terminal states of fully formed, specialized adult cells. These seemingly
contradictory observations have long perplexed scientists: How could such a diverse cadre of functionally
and morphologically distinct cell types result from genetically identical cells? How does a dividing cell
(e.g. liver) know to replicate into the same cell type (another liver cell)?
Conrad Waddington first introduced the concept of an “epigenetic landscape” to describe this
phenomenon in which differentiating cells lose the ability to return to a more pluripotent state (Waddington
1940; Gilbert 2012). Waddington’s use of “epigenesis” or “epigenetics” referred to the path cells take
during development from genotype to phenotype and also incorporated the understanding that
neighboring cells influence the differentiation of each other (Waddington 1939). The contributions of
neighboring cells (e.g. Shh signaling), or ‘extrinsic’ factors, have since been expanded to include any
environmental effects both ex vivo and in vivo. Modern definitions of “epigenetics” try to include the notion
of non-genetic heritability, traversing either cell divisions or generations, of such factors or phenomenon
to evoke the notion of cell identity “memory” (Hemberger et al. 2009).
In my opinion, the term “epigenetics” is highly sensationalized and used to describe observations
that go beyond the intention of its original definition, which has led to confusion and over use. For these
reasons, I avoid the use of the word “epigenetics,” but instead describe my observations and
understanding of the literature in the most concrete manner possible. On those occasions I do use the
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term “epigenetics,” I broadly refer to any modification of DNA or DNA architecture that does not change
the nucleic acid sequence. This work focuses on one of these modifications of DNA, the methylation of
cytosine residues, which plays an important role in bringing a cell from “genotype to phenotype” and in
determining cellular identity.

DNA METHYLTRANSFERASES CATALYZE THE METHYLATION OF CYTOSINE RESIDUES
The existence of methyl-modified cytosine (5mC) in nature was first discovered in 1925 by
Johnson and Coghill as a structural unit of nucleic acids isolated from tubercle bacillus (Johnson and
Coghill 1925) as anticipated by Wheeler and Johnson, the first to synthesize 5-methyl-cytosine in 1904
(Wheeler and Johnson 1904). More than two decades after Johnson and Coghill’s discovery, G. R. Wyatt
showed that 5mC occurred in the nucleic acids of higher animals and plants (Wyatt 1950). Studies would
later show that, unlike in plants (Gruenbaum et al. 1981), most animal 5mC occurs at the cytosine of a
cytosine-guanidine dinucleotide known as a CpG (Grippo et al. 1968). The only mammalian 5mC
occurring outside the CpG context was observed in embryonic stem cells and thought to be lost in adult
tissues (Ramsahoye et al. 2000; Meissner et al. 2008) until methylation studies of the developing mouse
and human brain revealed the presence of potentially biologically relevant levels of CpH (H = A, C, T)
methylation in neuronal cell types (Xie et al. 2012; Lister et al. 2013). The role of non-CpG methylation,
however, is still unclear. Mammalian genomes are depleted of CpG dinucleotides due to the propensity of
5mC to deaminate to thymine (Coulondre et al. 1978). This deamination has resulted in genomes
containing unmethylated CpG-rich regions, known as CpG Islands, primarily located in gene promoters
(Bird et al. 1985). CpGs outside of CGIs are typically methylated.
A family of proteins, known as the DNA methyltransferases (DNMTs), catalyzes the transfer of a
methyl group from S-adenosylmethionine to a cytosine residue (Gold et al. 1963; Grippo et al. 1968).
Four known DNMT proteins exist in mammals: Dnmt1 (Bestor et al. 1988), Dnmt3A/B (Okano et al. 1998),
and Dnmt3l (Aapola et al. 2000).
Work by Bessman et al. in 1958 characterizing the function of DNA polymerase showed that the
enzyme cannot distinguish between the methylated and unmethylated cytosine nucleotide (Bessman et
al. 1958) prompting the possibility for the existence of a methyltransferase responsible for propagating
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5mC through DNA replication. Dnmt1 serves this role due to its high affinity for hemi-methylated, newly
synthesized DNA (Gruenbaum et al. 1982; Bestor and Ingram 1983) and is primarily responsible for
faithfully copying the parental-strand methylation pattern onto the daughter strand after each round of
DNA replication (Stein et al. 1982), though some evidence exists that suggests Dnmt1 may have some de
novo methylase activity (Vertino et al. 1996). The localization of Dnmt1 to DNA replication foci (Leonhardt
et al. 1992) and its interaction with PCNA (Chuang et al. 1997), a protein that stabilizes the binding of
DNA polymerase to DNA, further strengthen the role it plays in maintaining DNA methylation states
through cellular division.
Dntm3a and Dnmt3b are responsible for the de novo methylation of unmethylated DNA (Okano et
al. 1998; Okano et al. 1999) and have both overlapping and disparate DNA sequence affinities. Although
somatic tissues show very little expression of Dnmt3a or Dnmt3b, Dnmt3a is ubiquitously expressed
throughout the early embryo while Dnmt3b expression is specific to the forebrain and eyes (Okano et al.
1999). The primarily role of Dnmt3b is to methylate minor satellite repeats of pericentric regions (Okano et
al. 1999) while Dnmt3a has been shown to methylate all CpGs regardless of genomic context (Shirane et
al. 2013). Beyond their role as de novo methylases, Dnmt3a and Dnmt3b seem to play a role in
methylation maintenance. Early knockout studies showed that embryonic stem cells lacking Dnmt3a and
Dnmt3b enzymes lose nearly all 5mC over progressive cell divisions, indicating Dnmt1 is insufficient to
fully maintain 5mC (Jackson et al. 2004). The most striking evidence of maintenance capability was
shown in Dnmt1 null colorectal carcinoma cells: even after 300 cell generations the cancer cells retained
~60% of their global 5mC (Rhee et al. 2000). A similar study using the same cell line but shRNA
knockdown, however, showed a dramatic loss of global and gene-specific methylation (Robert et al.
2003).
Dnmt3l has no active methylase domain but seems to play a role in ensuring proper methylation
of imprinted loci and transposable elements through the interaction with Dnmt3a and Dnmt3b. The
expression of Dnmt3l is confined to germ cells where it regulates the methylation status of the maternally
imprinted regions Snrpn, Necdin, Zfp127, Kcnq1ot1, and Peg3 (Bourc'his et al. 2001). Furthermore,
Dnmt3l has been shown to ensure methylation of transposons in male but not female germ cells
(Bourc'his and Bestor 2004). Dnmt3l directly binds to each of the catalytic domains of Dnmt3a and
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Dnmt3b, which increases their de novo methylation activity and ability to bind DNA (Gowher et al. 2005),
and directly binds histone modifications to recruit Dnmt3a to imprinted regions (Ooi et al. 2007). More
recently, Dnmt3l together with Dnmt3a have been shown to be responsible for CpG and non-CpG
methylation in oocytes (Shirane et al. 2013)

DNA METHYLATION IS IMPORTANT FOR MAINTAINING CELLULAR IDENTITY
The symmetry of a CpG dinucleotide on the forward and reverse strand provides a natural means
for ensuring 5mC states are faithfully inherited across DNA replication. Hence, DNA methylation is
thought to be the predominant mechanism by which cells maintain their cellular identity through cellular
divisions. The first evidence for a role of 5mC in maintaining cellular identity came two decades after
Wyatt’s discovery of vertebrae 5mC when Vanyushin et al. showed slight differences in the total 5mC
content of DNA between various animal tissues (Vanyushin et al. 1970). Using methylation sensitive and
insensitive enzymes, Waalwiik and Flavell showed significant 5mC difference between rabbit sperm,
brain, and liver DNA at an intron of the beta-globin gene locus (Waalwijk and Flavell 1978). Ehlrich et al.
would definitively demonstrate that global 5mC levels varied between tissue and cell types a few years
later (Ehrlich et al. 1982). These studies laid down the foundation for understanding the role of DNA
methylation in maintaining and determining cellular identify.
Several recent 5mC mapping studies at base pair resolution have demonstrated that cell types
show tissue-specific 5mC and are characterized by unique 5mC profiles that overlap among tissues of
similar origin. Varley et al. mapped the genome-wide distribution of 5mC across a diverse collection of 82
human cell lines and tissues and showed that individual cell types have very distinct 5mC profiles. They
show in vitro propagation of cell lines can cause a divergence from primary tissue 5mC levels (Varley et
al. 2013). This observation suggests loci that change 5mC levels in culture are dispensable, since these
cultured cells maintain their cellular identity. Ziller et al. mapped the entire 5mC landscape of 30 cell and
tissue types (Ziller et al. 2013); they find that roughly 22% of 5mC loci differ among normal cell types and
that tissues originating of similar origin share similar 5mC signatures.
The turn of the century saw the ushering in of cell reprogramming and induced pluripotent stem
(iPS) cells whereby somatic cells regain the capacity to differentiate into various germ cell types
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(Robinton and Daley 2012). The ability to restore pluripotency to somatic cells has provided significant
insight into the epigenetic mechanisms that underlie reprogramming and has shown that DNA methylation
plays a part in fixing a cell’s differentiated state and in conferring cellular memory (Kim et al. 2010; Polo et
al. 2010). Kim et al. rigorously showed that the cell type of origin influences the differentiation potential of
iPS cells (Kim et al. 2010). They showed that neural progenitor-derived iPS cells (NP-iPSCs) differentiate
much less efficiently into cells of hematopoietic lineage than iPS cells derived from bone marrow cells
(blood-derived; B-iPSCs), which are responsible for producing hematopoietic cells. The few
hematopoietic progeny that were differentiated from NP-iPSCs were reprogrammed to iPS cells (NPderived-blood-derived; B-NP-iPSCs), which subsequently were able to differentiate to hematopoietic
lineages at a very high efficiency. The poor blood forming potential of NP-iPSCs suggests that NPs either
have epigenetic marks that restrict the differentiation into blood fates or lack the epigenetic marks that
enable blood formation. Furthermore, Kim et al. demonstrated that treatment during differentiation of NPiPS cells with 5-azacytidine, a DNA methylation inhibitor, and TSA, a histone deacetylase inhibitor,
dramatically enhanced hematopoietic lineage formation. Most interestingly, derived iPS cells retained
residual DNA methylation that was indicative of their tissue of origin. Polo et al. also showed that iPSCs
derived from various cell types exhibited distinguishing DNA methylation signatures representative of their
cell type of origin (Polo et al. 2010). They expanded upon this understanding and showed that continuous
passaging erased these DNA methylation signatures to attenuate cell of origin effects.
Loss-of-function experiments in mice further support the important role of 5mC and the
methyltransferase machinery in maintaining cell identity (Broske et al. 2009; Sen et al. 2010; Dhawan et
al. 2011b). A study of the epidermal progenitor population showed that Dnmt1 is necessary for proper
differentiation into keratinocytes and for maintaining a self-renewing state (Sen et al. 2010). Dnmt1
knockdown with shRNAs in progenitors resulted in induced differentiation and a loss of self-renewal
ability. Wild-type DNMT1, but not a catalytically inactive mutant, reversed the observed proliferation
defects, suggesting that the methylation of DNA controls proliferation and differentiation induction in
epidermal progenitors. Furthermore, differentiation induction also occurred in human muscle progenitors
upon Dnmt1 knockdown.
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The functional disruption of Dnmt1 in mice was shown to abrogate the differentiation of
hematopoietic stem cells (HSCs) into myeloerythroid and lymphoid lineages (Broske et al. 2009). Broske
et al. show that Dnmt1 maintains high methylation levels at myeloerythroid-specific genes to repress
transcription. Failure to maintain methylation at these genes in HSCs prevents the differentiation into
lymphoid progeny. Indeed, Dnmt1-depleted HSCs differentiated only down the myeloid lineage
suggesting hypermethylation of myeloerythroid genes is necessary for proper differentiation into lymphoid
cells. Interesting, the removal of Dnmt1 from committed lymphoid cells did not disrupt lymphoid identity or
maturation, suggesting the maintenance of methylation is only necessary for lymphoid differentiation and
not necessary for the maintenance of lymphoid cellular identity.
Most striking is a study demonstrating that pancreatic β cells, which produce insulin, undergo
transdifferentiation to glucagon-producing α cells upon the conditional disruption of Dnmt1 (Dhawan et al.
2011b). Using a genome-wide profiling method, they found that a short region upstream of Arx, a gene
expressed specifically in α cells, lost methylation in Dnmt1-null β cells. Upon demethylation of Arx, β cells
began to downregulate β cell markers and upregulate α cell markers. The inhibition of DNA methylation
with 5-azacytidine also induced an upregulation of Arx de-repression, α cell marker activation, and
glucagon production demonstrating that the methylation state of Arx determines the cellular identity of
pancreatic β cells.

DNA METHYLATION AS A MECHANSIM OF STABLE GENE SILENCING
The mechanistic function of 5mC did not become apparent until 1977 when Christman et al.
observed gene expression increases of globin genes in erythroleukemia cells cultured in the presence of
L-ethionine (Christman et al. 1977). They showed that L-ethionine resulted in a loss of global 5mC. Using
methylation sensitive endonucleases, McGhee and Ginder were the first to interrogate the 5mC levels of
a specific locus to understand its correlation with gene expression (McGhee and Ginder 1979). By
assessing 5mC and expression levels of the β globin gene in normal chicken tissues, they showed
tissues that expressed or that had expressed β globin had sites at the ends of the gene sequence that
were fully unmethylated; the same sites were at least partially methylated in tissues that did not express β
globin. Desrosiers et al. documented a similar observation in virus producing and non-producing cells
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(Desrosiers et al. 1979). Gene transfection experiments further showed that in vitro methylation of gene
constructs inhibits their expression (Fradin et al. 1982) while many endogenous genes can be activated
from a repressed state by treatment with 5-azacytidine, an inducer of demethylation (Jones and Taylor
1980). Global methylation and gene expression profiling would eventually show that the methylation of
CpGs upstream of genes results in their down-regulation (Walsh et al. 1998; Bird and Wolffe 1999) and
would establish 5mC as a transcription regulator.
The effects of DNA methylation, however, are strongly dependent on genomic context. Although
5mC in gene promoters and enhancers are correlated with gene silencing, gene body methylation is
associated with transcriptionally active genes (Hellman and Chess 2007; Ball et al. 2009). Many genomewide studies have shown poor overall correlations of 5mC with gene expression (Eckhardt et al. 2006;
Zilberman et al. 2007; Brenet et al. 2011; Hartung et al. 2012). These inconsistencies are most likely a
result of our inability to accurately identify the regulatory regions for all genes, as most can occur very
distal to transcription start sites.
The covalent bond attaching the methyl group to the 5` carbon of a cytosine ensures methyl
markers are stable and not easily lost. The durable nature of DNA methylation allows for the long-term
silencing of genes and other genomic elements within specific cellular contexts. Dormant transposable
elements pose a threat to the stability of the genome if reactivated. DNA methylation functions to silence
transposable elements and maintain chromosomal integrity (Slotkin and Martienssen 2007) by preventing
the reactivation of endoparasitic sequence that cause translocations and gene disruptions (Esteller 2007).
DNA methylation is also responsible for silencing the inactive X chromosome during female X inactivation
(Mohandas et al. 1981) and for ensuring allele-specific expression from paternal or maternal copies at
imprinted regions (Reik et al. 1987; Sapienza et al. 1987).
The mechanism by which DNA methylation represses transcription can be direct, by excluding
the binding of proteins that affect transcription (Watt and Molloy 1988), or indirect, by recruiting methylCpG-binding proteins and their associated repressive chromatin remodelers (Robertson 2005).
The chromatin boundary element binding protein, CTCF, acts to insulate the effects of enhancer regions
from gene promoters by binding between these genomic elements. Its DNA binding sequence contains a
CpG which when methylated inhibits (Ohlsson et al. 2001) CTCF from binding DNA. The imprinted gene
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H19 is repressed on the paternal chromosome through the methylation of an imprinted-control region 2
kilobases from its transcription start site. The same imprinted-control region is unmethylated on the
maternal chromosome where CTCF binds to block the effects of a H19 enhancer on the Igf2 gene and
maternally repress the Igf2 gene (Hark et al. 2000). Other methylation sensitive and insensitive binding
proteins abound, but their role in regulating expression is unclear (Tate and Bird 1993). While CTCF is
inhibited by 5mC, several proteins explicitly bind 5mC. Mecp-1 (now known as Mecp2) was the first
protein shown to bind specifically to methylated DNA sequences (Boyes and Bird 1991), but several
others have since been described (Wade 2001). Methyl-binding proteins mediate gene silencing by
recruiting histone-modifying factors that shift the chromatin architecture to a closed, inaccessible, and,
therefore, repressed state (Jones et al. 1998; Nan et al. 1998). MECP2, for example, recruits the arginine
methyltransferase, PRMT6, among others, to add repressive chromatin marks and remove activating
chromatin marks at the Arx locus to repress transcription (Dhawan et al. 2011b).

DNA METHYLATION AND NEURONAL DEVELOPMENT AND FUNCTION
The past decade has accumulated significant insights into the role DNA methylation plays in
neuronal development and postnatal function. Lister et al have shown that the mouse and human brain
undergo significant methylation reconfiguring during development and highlight the potential importance
of non-CpG methylation (Lister et al. 2013). They show that the fetal cortex is practically devoid of CpH
methylation but rapidly gains global methylation at CpH dinucleotides shortly after birth during a time of
high synaptogenesis. CpH methylation in gene bodies was inversely correlated with gene expression
which is consistent with the role of 5mC in repressing transcription. Large, non-centromeric megabase
regions of the genome, however, were resistant to CpH methylation gains and contained genes that
encode receptors required for sensory neuron function and immune function. This study suggests
neurons of the brain undergo significant gene repression via 5mC gains in the CpH context between fetal
and adult stages. Several studies characterizing 5mC levels show that the human cerebral cortex
undergoes significant 5mC changes throughout an individual’s lifespan showing gradual as well as sharp
gains in 5mC levels at various promoters (Siegmund et al. 2007). Many 5mC changes were associated
with transcriptional decline, though the consequences, if any, of these changes are not clear (Hernandez
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et al. 2011). Contrary to these studies, Lister et al showed CpG and CpH methylation declines with age
post-adolescence. The discordance of these studies most likely lies in the fact that Lister et al
interrogated the whole genome while the previous studies were much less comprehensive.
The adult brain can undergo significant neurogenesis in response to external stimuli resulting in
advanced structural plasticity. The methylation of DNA plays an important role in this observed plasticity,
including in synaptic formation (Levenson et al. 2006), learning and memory (Day and Sweatt 2010; Miller
et al. 2010; Zovkic et al. 2013), emotional behavior (Lubin et al. 2008; LaPlant et al. 2010), adult
neurogenesis (Ma et al. 2009), and age-related cognitive decline (Oliveira et al. 2012). Most interestingly,
is the role of 5mC in neural plasticity and neurogenesis, as various studies have shown that neuronal
activity leads to significant gains and losses of 5mC in the brain (Nelson et al. 2008; Miller et al. 2010).
For example, the promoter of Bdnf, a gene important for adult neurogenesis, is regulated in an activitydependent manner (Martinowich et al. 2003; Ma et al. 2009). Upon synchronized electro-convulsion of the
hippocampus, the Bdnf promoter is demethylated by Gadd45b within 4 hours, which causes a release of
the MECP2 repressor complex and increased expression of Bdnf. The study further shows that Gadd45b
is essential for neural progenitor proliferation and activity-induced dendritic development (Ma et al. 2009).
Global profiling studies have revealed the plasticity of 5mC in the brain across several genes (Guo et al.
2011a). Persistent activity in neurons, as occurs during electroconvulsive stimulation or exercise, leads to
subtle yet significant 5mC losses at Per2, Crebbp, and Grip1 and also 5mC gains at Zfhx2 and Ccdc44.
Most of these 5mC changes occur at exonic and intronic regions, which may explain why these 5mC
alternations do not correlate well with gene expression. These studies showing that significant 5mC
configuration occurs after neuronal activity are helping to expel the belief that DNA methylation is highly
stable in terminally differentiated cells.
Glial cells (i.e. astrocytes, oligodendrocytes, and microglia) and neurons are both derived from
the same neuron progenitor cell population. Proper DNA methylation establishment seems to play an
important role in the fate determination of neural progenitor cells into neurons and glial cells. Neuron and
non-neuron cells display unique global methylation profiles, which ensures the regulation of neuronal- and
glial-specific transcription (Iwamoto et al. 2011). Glial cells support the viability of neurons and therefore
arise after the formation of neurons from the same neuronal progenitor cells (NPCs) (Qian et al. 2000).
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Indeed, during development, NPCs gradually acquire competence for gliogenesis (Sauvageot and Stiles
2002). Once NPCs are gliogenic, they simultaneously lose the ability to differentiate into neurons,
suggesting the existence of a neurogenic to gliogenic switch that occurs during central nervous system
development. Indeed, neurons appear at embryo day 11.5 (E11.5) while astrocytes begin to appear at
E14.5. This switch in differentiation ability is regulated by 5mC. Before E14.5, the promoter of Gfap, an
astrocyte marker, is methylated at a Stat3 binding site in neuroepithelial (progenitor) cells (Takizawa et al.
2001). At E14.5, neuroprogenitor cells lose methylation at this site which leads to Stat3 binding, Gfap
activation, and astrocyte differentiation. Studies of conditional Dnmt1 knockout mice further validate the
role of 5mC in neuron/glial differentiation. Fan et al. show that Dnmt1-deficient NPCs are marked by
hypomethylation at the Gfap promoter and spontaneously differentiate into glial cells (Fan et al. 2005).
Upon Dnmt1 inactivation, glia-associated transcription factors, but not neuronal-specific genes are
activated.
Direct experimental findings have shown that the DNA methyltransferases Dnmt1 and Dnmt3a
are important for learning, memory, and synaptic plasticity. Conditional mutant mice lacking Dnmt3a in
the entire central nervous system develop normally but have significant neuromuscular defects, reduced
number of motor neurons in the brain stem, and shortened life spans (Nguyen et al. 2007). Because the
knockout induction occurrs in neuron progenitor cells, these experiments highlight the importance of
Dnmt3a in neuron differentiation. Exclusive conditional knockout of Dnmt1 and Dnmt3a in post-mitotic
neurons of mice results in learning and memory deficits (Feng et al. 2010). Here, Dnmt gene deletion only
occurs in mature, post-mitotic neurons of the central nervous system allowing researchers to understand
their role in mature neuron function. Dnmt1 and Dnmt3a single knockout mice did not show an
appreciable phenotype while double knockout animals had normal lifespans but smaller hippocampi.
Furthermore, double knockout mice showed an appreciable loss of neuronal DNA methylation, induction
of immune genes, and impaired synaptic plasticity. As we continue to profile the methylation and
transcriptional landscapes of neurons under various conditions, the role of 5mC in neuron function will
only become more evident. Furthermore, the reversibility and ability to regulate gene expression makes
DNA methylation an attractive target for therapies that may be able to activate aberrant gene silencing or
silence aberrant expression profiles.
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DNA METHYLATION IN HUMAN HEALTH
The importance of DNA methylation in development has been well describing using transgenic
and knockout mice. Deletion of Dnmt1 is lethal to embryonic development (Li et al. 1992); Dnmt3bdeficient mice do not reach full term while mice lacking Dnmt3a die within 4 weeks of birth (Okano et al.
1999). Dnmt3l-null mice are viable and develop normally (Bourc'his et al. 2001); The heterozygous
offspring of female mice lacking Dnmt3l, however, die before the mid-gestation period from the biallelic
expression of imprinted genes normally methylated and silenced on the allele of maternal origin while
male mice lacking Dnmt3l are sterile due to a lack of germ cells in the adult. The importance of DNA
methylation is further emphasized by the growing number of human diseases that are known to occur
when 5mC is not properly established and/or maintained (Robertson 2005; Jakovcevski and Akbarian
2012). Indeed, aberrant DNA methylation has been broadly implicated in cancer and in numerous
neurological diseases.

Cancer
DNA methylation was first implicated in cancer by Feinberg and Vogelstein in 1983 when they
observed significant 5mC differences at specific loci between normal and diseased tissues of four cancer
types (Feinberg and Vogelstein 1983). They also found the lowest level of 5mC in the metastasis of a
lung tumor, first demonstrating that cancer cells lose methylation as they progress. The aberrant
methylation patterns observed in cancers have since been well documented (Portela and Esteller 2010;
Sharma et al. 2010; Taby and Issa 2010). Tumors are often characterized by global hypomethylation
(Goelz et al. 1985; Wilson et al. 2007) as well as by locus-specific hypermethylation of genes involved in
the main cellular pathways (Portela and Esteller 2010). The global hypomethylation, which can occur in
large megabase regions and unmethylates repetitive regions (Hansen et al. 2011), is thought to
destabilize the genome and result in transposon-mediated rearrangements. Loss of methylation also
causes the aberrant activation of growth promoting genes (Wilson et al. 2007) and the loss of imprinting
(Reik and Lewis 2005). Hypermethylation primarily at CGIs of promoters, on the other hand, contributes
to tumorigenesis by silencing tumor suppressor and DNA repair genes and could thus serve as the
second hit in Knudson’s two-hit model (Suzuki et al. 2004; Weinberg 2007). Roughly 5-10% of CGIs that
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are constitutively unmethylated in adult tissues are hypermethylated in cancer (Bird 2002; Weinberg
2007). The aberrant methylation of normally unmethylated tumor-suppressor genes can causes loss of
heterozygosity and uncontrolled cell division and proliferation in countless cancers (Jones and Baylin
2002; Chen et al. 2003). Today, hypermethylation events are being used as biomarkers to screen for
colorectal cancer, among others (Lofton-Day et al. 2008). Abnormal 5mC in conjunction with disruptions
in histone modifications may be key initiating events in some forms of cancer (Feinberg et al. 2006a).
The onset of whole genome and exome sequencing efforts have revealed the presence of
mutations in chromatin modifying proteins as well as DNA methyltransferases across many tumor types
suggesting the aforementioned methylation aberrations could be downstream of genetic abnormalities. To
date, over 15% of hematopoietic and lymphoid cancers catalogued in the COSMIC database show
mutations in the de novo methyltransferase DNMT3A, with enrichment in patients with de novo acute
myeloid leukemia (AML) (Ley et al. 2010). Mutations in DNMT3A were correlated with poor patient
survival, suggesting DNMT3A is involved in AML disease progression. Despite most mutations occurring
in the methylase domain of DNMT3A, genome-wide 5mC analysis of AML genomes with and without
DNMT3A mutations did not reveal an appreciable difference in 5mC between the two samples.
Furthermore, the few differences that were observed did not result in an expression change of the nearest
genes. These observations suggest that the function of DNMT3A in cancer progression may not be due
to altered DNA methylation, but rather related to its ability to bind DNA and recruit histone modifiers (Ley
et al. 2010). Few mutations are observed in DNMT3B for any cancer type, highlighting the primarily role
of DNMT3B in early development. Similarly, very few mutations have been observed in DNMT3L of
tumors catalogues in the COSMIC database. Over 50% of lung cancers, however, show copy number
variations of DNMT1 and most non-small cell lung cancer tumors show an over-expression of DNMT1,
DNMT3A, and DNMT3B protein and show increases in 5mC at tumor suppressor genes (Lin et al. 2007).
The observation that pharmacological DNA methylation inhibitors, such as 5-azacytidine, results
in gene activation (Venolia et al. 1982) demonstrated that 5mC is reversible and has since ushered in
DNA methylation inhibitors as potent cancer therapies. Several DNA methyltransferase inhibitors have
been approved in the past decade by the FDA for the treatment of patients with AML or myelodysplastic
syndrome (Kaminskas et al. 2005). The response rates to the drugs, however, are low and highly variable
12

among patients. Furthermore, it is unclear whether the beneficial effects of treatment are associated with
DNA methylation (Silverman et al. 2002; Figueroa et al. 2009).

Neurological Diseases
DNA methylation has been strongly implicated in diseases affecting the nervous system either
directly, by the aberrant methylation of DNA (Kumari and Usdin 2009; Buiting 2010), or indirectly, through
functional loss of the DNA methyltransferases machinery (Jin et al. 2008; Chestnut et al. 2011; de Greef
et al. 2011; Klein et al. 2011) or through the disruption of methyl-binding proteins (Amir et al. 1999).
Fragile X Syndrome, a form of mental retardation, is caused by inactivation of the FMR1 gene through
aberrant methylation of its promoter sequence. Aberrant methylation is also responsible for loss of
imprinting in Prader-Willi Syndrome and Angelman Syndrome, which disrupts cognitive development in
childhood. Mutations in DNMT3B and DNMT1 and the resultant disruption of proper methylation is the
cause of two rare neuropathies Immunodeficiency, Centromere instability and Facial anomalies
Syndrome 1/2 (ICF1/2) and Hereditary Sensory and Autonomic Neuropathy type 1, respectively, while all
three methyltransferases have recently been implicated in Amyotrophic Lateral Sclerosis (ALS), the motor
neuron degenerative disease. Finally, Rett Syndrome, one of the most studied neurological diseases, is
caused by the disruption of the methyl-CpG-binding protein, MECP2, and characterized by early-stage
cognitive decline.
Several neurological diseases are directly caused by the aberrant loss or gain of 5mC at a single
locus including repeat-instability disease (Kumari and Usdin 2009) and imprinting disorders (Robertson
2005). Fragile X Syndrome, a common form of mental retardation (Martin and Bell 1943), is caused when
the CGG trinucleotide-repeat within the 5`-UTR of the FMR1 gene extends beyond 200 repeats. At this
length, the CGG-repeat becomes methylated and the FMR1 gene is silenced leading to improper
synthesis of neuron-specific proteins (Penagarikano et al. 2007). Recent work has shown that repression
occurs because FMR1 mRNA hybridizes to the complementary CGG-repeat portion of the FMR1 gene
(Colak et al. 2014). Future work will reveal how the DNA methyltransferase machinery is recruited to the
RNA·DNA duplex and whether the hypermethylation can be permanently reversed. Two forms of mental
impairment can occur when a single imprinted locus is not properly methylated and regulated. Prader-
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Willi Syndrome and Angelman Syndrome are caused by a loss of imprinting either through chromosomal
loss or by aberrant methylation at the 15q11q13 chromosomal region (Buiting 2010). Prader-Willi occurs
when imprinting is lost on the paternal allele while Angelman occurs when imprinting is lost from the
maternal allele (Glenn et al. 1993).
Hereditary sensory and autonomic neuropathy type 1 (HSAN1) is the only disease known to be
caused by mutations in the DNA targeting domain of DNMT1 (Klein et al. 2011). Patients with HSAN1
suffer from late onset dementia, hearing loss, and loss of pain sensation due to peripheral and central
neuron degeneration. The disruption of this domain results in premature protein degradation, reduced
methyltransferase activity, and impaired heterochromatin binding during the G2 cell cycle phase which
leads to a moderate global loss of methylation, primarily in repetitive satellite elements, and modest sitespecific hypermethylation (Klein et al. 2011). Although DNMT1 is primarily considered to only function in
dividing cells, these studies ascribe a novel function to DNMT1 in post-mitotic neurons, namely in
ensuring the proper methylation of pericentric and other condensed portions of the genome (Easwaran et
al. 2004).
The ICF syndromes affect multiple organs and are characterized by mental retardation and
defective brain development. ICF1 is caused by partial loss-of-function mutations in the catalytic domain
of DNMT3B and the attendant loss of 5mC at pericentric repeats and gene promoters, which leads to
dysregulation of genes involved in neurogenesis, immune function, and development (Jin et al. 2008).
Interestingly, patients with ICF2, a syndrome with identical pathologies as ICF1, have completely
functional DNA methyltransferase proteins but lack functional copies of the putative transcriptional
repressor, ZBTB24 (de Greef et al. 2011). Hypomethylation defects are also present in ICF2 patients but
occur at slightly different pericentric satellites, which implicates ZBTB24 in regulating DNA methylation.
ALS is one of a handful of neurodegenerative diseases that results as a consequence of motor
neuron axonal degradation. Unlike the previously discussed neurological disorders, ALS is an affliction of
the upper and lower somatic motor neurons located in the spinal cord that enervate skeletal muscles to
control movement and locomotion. Although less well established, DNA methylation may be associated
with ALS. One recent study showed that DNA methyltransferases play a role in regulating apoptosis in
motor neurons, which suggests a novel function for the methyltransferase machinery (Chestnut et al.

14

2011). They show that Dnmt3a mediates apoptosis in chemically or physically challenged motor neurons
through interactions with the mitochondria and through increasing genomic and mitochondrion 5mC.
Inhibition of the methyltransferases prevents the induction of apoptosis demonstrating their role in
maintaining motor neuron viability. Remarkably, motor neurons affected by ALS showed a significant
overexpression of Dnmt3a as well as hypermethylation of genomic and mitochondrion DNA. This study
alludes to the possibility of treating ALS with methyltransferase inhibitors.
The early onset autism spectrum disorder, Rett Syndrome, is caused by dysfunction of the
aminergic neurons of the brainstem. The X-linked gene methyl-CpG-binding protein, MECP2, is
responsible for regulating a cadre of genes involved in neurogenesis and neuron function. MECP2 has
been shown to act by binding 5mC and recruiting chromatin-modifying factors that reorganize the
chromatin into a closed and repressive state (Amir et al. 1999) although various studies have suggested
an activating role of MECP2 (Li et al. 2011). Mutations in MECP2 preclude effective binding to methylated
cytosines and recruitment of these repressive factors (Chahrour et al. 2008). Encouragingly, the
restoration of Mecp2 in the post-mitotic neurons of Mecp2-deficient mice recovers most Rett syndrome
symptoms (Guy et al. 2007) demonstrating that the lack of Mecp2 does not irreversibly damage neurons
and that Rett is not strictly a neurodevelopment disorder.
The occurrence of DNA methylation-associated neurological diseases highlights an underappreciated role of DNA methylation, namely in ensuring proper function of post-mitotic cells. Previously,
DNA methylation was only thought of in the context of cell division and early development. These
diseases – and the ability to recover normal function in the case of Rett Syndrome – have shifted the
notion of 5mC as a static, permanent mark, important only in development, to a dynamic mark of
significant relevance to the human postnatal and adult brain. As we continue to explore the role of 5mC in
post-mitotic neurons, we will undoubtedly uncover new regulatory functions of the DNA methylation
machinery and associated binding partners.

TECHNOLOGICAL CHALLENGES AND LIMITATIONS FOR MAPPING DNA METHYLATION
Current technologies that measure DNA methylation are limited by cost, sample throughput, the
requirement for a large amount of starting material, and the inability to analyze DNA methylation of
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complex tissues. Because PCR amplification erases DNA methylation patterns, a methylation-dependent
treatment is required before methylation readout. The two main approaches to determining methylation
patterns or profiles are affinity enrichment and bisulfite treatment. Where previous technologies limited
DNA methylation analysis to a single locus, the introduction of microarray hybridization experiments and
next-generation sequencing has permitted the profiling of 5mC at the genomic scale (Laird 2010a). Many
of the earliest techniques used to measure DNA methylation have been supplanted by next-generation
sequencing approaches (Esteller 2007). Today, discovery and profiling studies use genome-wide
approaches while validation and targeted experiments use locus-specific approaches to determine the
methylation status of the genome in disease and development.

Genome-wide approaches
Current genome-wide sequencing-based approaches for DNA methylation analysis vary in
resolution, coverage, and accuracy (Bock et al. 2010; Harris et al. 2010). Affinity enrichment-based
techniques (e.g. MeDIP-seq, MethylCap-seq, and MBD-seq) can theoretically cover 100% of the genome
but at a 100-1,000 base pair resolution. The actual 1x and 10x coverage of affinity enrichment published
experiments is about 60-67% and 10-20% respectively, which indicates that increased coverage would
require significant sequencing to reach saturation (Beck 2010). Furthermore, 70-80% of reads of whole
genome sequencing provide no information of CpG methylation due to the non-uniform distribution of
CpG dinucleotides (Ziller et al. 2013). Recently developed algorithms when coupled with the methylationdepletion technique MRE-seq have increased the resolution of these tools to CpG resolution (Stevens et
al. 2013). The benefit of these methods is the unbiased representation of the genome to include interand intragenic regions, promoters, and repetitive regions. An alternative whole genome approach to
methyl-affinity enrichment is whole genome bisulfite shotgun sequencing (MethylC-seq)(Lister et al.
2009). The treatment of DNA with sodium bisulfite transforms the epigenetic methylation mark into a
genetic mark by only converting unmethylated Cs to Ts (by uracil)(Frommer et al. 1992) and can
therefore be translated using sequencing. Bisulfite approaches have quickly become the gold standard for
methylation analysis because of its single base pair resolution, independence of CpG methylation status,

16

and ability to interrogate almost any region in the genome. The most inclusive platform, MethylC-seq,
however costs an estimated $30,000 per sample (personal calculation).
A more economical alternative to MethylC-seq is reduced representation bisulfite sequencing
(RRBS), which capitalizes on the non-uniform distribution of CpGs across the genome (Meissner et al.
2008). Most CpGs are concentrated in CpG Islands (CGI). CGI appear in 60% of promoters and often
show aberrant methylation in cancer (Jones and Baylin 2007). RRBS enriches for these regions with high
CpG content, so that, instead of covering the entire genome, RRBS effectively reduces the portion of the
genome that is sequenced to ~10% (Bock et al. 2010). Furthermore, when detecting differentially
methylated regions (DMR) between two embryonic stem cell lines, RRBS was able to detect 1,000 DMRs
with only 15 million reads per sample whereas MeDIP-seq required more than 30 million reads to detect
1,000 DMRs (Bock et al. 2010). RRBS is an attractive choice for analyzing promoter and CGI
methylation, which play an important role in regulating genes in human cancers (Jones and Baylin 2007).
Until recently, genome-scale DNAme profiling technologies requires a significant amount of
starting DNA. Targeted padlock probes require >200 ng of bisulfite treated DNA (Deng et al. 2009);
MeDIP-seq has been optimized for 30-120 ng (Borgel et al. 2010); and MethylC-seq requires several
micrograms of DNA (Lister et al. 2009). New innovations in Illumina library preparations using
transposon-mediated adapter insertions, however, have allowed for whole genome bisulfite sequencing
on 10 ng of DNA (Adey and Shendure 2012). At present, RRBS can be reproducibly performed on <1 ng
of purified input DNA (Smith et al. 2012). Furthermore, LCM-RRBS, presented in this thesis, functions on
<2 ng of DNA extracted from laser capture microdissected tissues (Schillebeeckx et al. 2013).

Locus-specific approaches
Low-throughput validation assays are common for interrogating the 5mC status of a limited
number of genomic loci. Whole genome or genome-wide discovery studies identify differentially
methylated regions, which must be validated independently by orthogonal methods. Various locusspecific methods exist that vary in complexity, labor, quantitative resolution, and number of CpGs
interrogated. The most useful and most commonly used techniques fall into three categories:
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endonuclease techniques, methylation-specific PCR techniques, and bisulfite sequencing techniques.
Each category has many variations of the basic assay; the basic principals are described here.
Methods leveraging the specificity of endonucleases are able to interrogate the qualitative level of
5mC at one specific CpG or CpH (Xiong and Laird 1997). In this method, broadly referred to as COBRA,
bisulfite-treated DNA is amplified using primers specific to converted DNA. The DNA is then digested with
the endonucleases, BstUI and TaqI, which contain a converted or unconverted CG sequence in their
binding sites. Methylated DNA would prevent bisulfite conversion and therefore eliminate the binding site
whereby preventing digestion, whereas unmethylated DNA would allow digestion. Various methods
employ different endonucleases depending on the sequence of the site of interest. The HELP assay does
not rely on bisulfite conversion (Khulan et al. 2006). Instead, the methylation sensitive and insensitive
enzyme, HpaII and MspI, are used to digest DNA. The HpaII-digested DNA fraction represents
unmethylated DNA while the MspI-digested fraction serves as the background, “input” control. Digested
DNA can either be amplified with site-specific primers or ligated with universal oligonucleotides and
hybrized to microarrays. COBRA provides a fairly quick qualitative assessment of 5mC at one or two
specific sites, but is limited by interrogating 5mC at sites with an endonuclease’s sequence recognition
motif.
Methylation-specific PCR techniques also rely on bisulfite conversion to translate 5mC into a
nucleic acid mark. One such assay, called MethylLight, is quantitative and highly sensitive, capable of
detecting methylated alleles in the presence of 10,000-fold excess unmethylated alleles (Eads et al.
2000). In the MethylLight assay, genomic DNA is first bisulfite treated to create methylation-dependent
sequence differences. Quantitative PCR is next performed using primers that overlap CpG regions and
only anneal if methylated (unconverted). The PCR reaction can also be done under non-quantitative
conditions and visualized on an agarose gel to qualitatively assess methylation levels. Like restrictionbased assays, methylation-specific PCR only interrogates one CpG per reaction, which significantly limits
the assay’s throughput and utility.
The most common locus-specific methylation mapping method, bisulfite-specific PCR, consists of
bisulfite conversion, PCR amplification, and sequencing (Sasaki et al. 2003). Bisulfite conversion of DNA
can result in the creation of abasic DNA backbones resulting in brittle DNA that easily degrades or
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sheers. Large amplicons are, therefore, difficult to amplify by bisulfite-specific PCR. Nonetheless, 6001,000 base pair amplicons can readily be amplified from bisulfite converted DNA using primers designed
to anneal to converted DNA. Here, the primers do not contain any CpG sequence which allows for
unbiased, methylation-agnostic amplification. Amplified products can be sequenced using next-gen (e.g.
Illumina) sequencing, Sanger sequencing, or pyrosequencing. For Illumina sequencing, primers are
typically designed with Illumina adapters in the tails; amplicons can also be sequenced using standard
library preparation methods. Percent methylation is calculated by determining the fraction of total reads
that are methylated. Sanger sequencing requires that amplicons be ligated into a vector and individual
clones sequenced. Because each clone represents an individual molecule, 10-15 clones must be
sequenced to accurately quantify the percent methylation. Finally, if a biotinylated primer is used during
the PCR amplification, the amplicon can be sequenced using a pyrosequencing machine. Here, additional
primers designed roughly 30 base pairs from a CpG are annealed to complete the sequencing reaction.
Because pyrosequencing is inherently quantitative, percent methylation can be directly calculated from
the reaction. Successful bisulfite-specific PCR on a single locus has been performed on as little as 8 cells
collected from an embryo and laser capture microdissected tissue samples. (Millar et al. 2002). Bisulfitespecific PCR is robust, sensitive, and allows for the interrogation of all CpGs within an individual
amplicon.

SCOPE OF THESIS WORK
Although often considered homogenous, tumors consist of histologically diverse tissues
(Weinberg 2007) that display intratumor heterogeneity in gene expression, genotype, and metastatic and
proliferative potential (Fidler et al. 1979; Heppner 1984). This heterogeneity impedes the investigation
and treatment of tumors because tissue samples may not be representative of the entire tumor (Michor
and Polyak 2010). Therefore, the ability to profile methylation genome-wide in a small number of cells is
crucial to analyzing 5mC in complex tissues like tumors. Such a tool would enable the use of laser
capture microdissection to separate heterogeneous cell types from one another. This thesis describes a
novel method, called Laser Capture Microdissection-Reduced Representation Bisulfite Sequencing (LCMRRBS), that accurately maps genome-wide 5mC of cells isolated using laser capture microdissection.
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The method was applied to understand what 5mC changes, if any, occur in gonadectomy-induced
adrenocortical neoplasias in mice. Furthermore, LCM-RRBS was applied to pure motor neuron cultures at
early and late stages to elucidate the role of 5mC in motor neuron maturation.
Chapter 2 addresses the need for a novel technique that can map 5mC genome-wide of very few
cells. I show that LCM-RRBS accurately and reproducibly profiles genome-wide methylation of DNA
extracted from microdissected fresh frozen or formalin-fixed paraffin-embedded tissue samples. The
LCM-RRBS method adapts Illumina library preparation techniques to minimize sample loss and to pool
multiple samples together and uses laser capture microdissection (LCM) to isolate specific populations of
cells. I applied LCM-RRBS to character the methylation of adrenocortical neoplasias and was able to map
2

genome-wide 5mC of isolated neoplastic and adjacent normal tissue using less than 10 mm of fresh
frozen tissue. In one multiplexed experiment, we interrogated the methylation status of >13,000
promoters and >13,000 CpG Islands of 6 tissue samples (3 neoplastic and 3 normal representing 3
different mice) across an average of >800,000 CpGs per sample. We identified 37 and 8 promoters of
genes implicated in adrenal and gonadal function that showed significant loss or gain of 5mC,
respectively, in neoplastic relative to normal tissues. This chapter is the proof-of-concept for LCM-RRBS
and demonstrates the method’s utility.
Chapter 3 is a follow-up to the study described in Chapter 2. We hypothesized that adrenocortical
neoplasms that result from gonadectomy develop a gonadal phenotype. To test this hypothesis, we took
several approaches. First, we show that Igfbp6 and Foxs1, which are differentially methylated, are also
differentially expressed at the transcript and protein level between neoplastic and normal adrenal tissues.
Second, we applied transcriptome profiling to identify three novel gonadal markers that were upregulated
in adrenocortical neoplasms. Finally, enrichment analysis demonstrated that genes upregulated in the
adrenal glands of gonadectomized mice were more likely to be highly expressed in ovary or testis but not
in the non-steroidogenic tissue brain. Furthermore, genes downregulated in the adrenal glands of
gonadectomized mice were more likely to be highly expressed in the normal adrenal tissue. Together,
these findings suggest that adrenal neoplasms exhibit mixed characteristics of male and female gonadal
somatic cells and, therefore, represent a possible example of cell type transformation involving 5mC
configuration.
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In Chapter 4, I describe the 5mC profiles of early and late stage maturing motor neurons using
LCM-RRBS. The Hb9-puro RW4 mouse embryonic stem cells have a puromycin transgene driven by the
Hb9 enhancer. Hb9 is exclusively expressed in motor neuron precursors and early differentiated motor
neurons allowing for the selection of pure populations of motor neurons in culture. We find that motor
neurons lose and gain 5mC at 2,894 and 1,147 CpGs, respectively, between 24 hours and four days after
selection with puromycin. Many of the hypomethylated CpGs were near genes important for motor neuron
function that showed a gain in expression over time. I show that hypomethylated regions are enriched for
known motor neuron-specific transcription factors like Isl1, Lhx3, Phox2a, and Tbx20. Furthermore, we
show that motor neurons gain 5-hydroxymethylation (5hmC) as they mature. Because Hb9-expressing
cells are post-mitotic, this configuration in 5mC is due to active pathways suggesting a role for Dnmt3a,
Dnmt3b, and the Tet family of proteins. To test this hypothesis, we derived Tet1, Tet2, and Tet3 single,
double, and triple knockout Hb9-puro lines using the CRISPR/Cas9 genome engineering system. We find
that individual Tet genes are dispensable for motor neuron differentiation and maturation and, therefore,
play redundant roles. Knockout of Tet1 and Tet2 together significantly reduced differentiation potential but
resulted in mature motor neurons and normal 5hmC gains over time. Finally, knockout of all three Tet
genes prevented efficient differentiation and resulted in the differentiation of very few mature motor
neurons. Together, our findings highlight a new role for 5mC and 5hmC in motor neurons suggesting
5mC and 5hmC configuration during motor neuron development is necessary for proper functional
maturation.
This body of work makes several contributions to the field of DNA methylation. First, the
development of LCM-RRBS allows for genome-wide 5mC mapping of laser capture microdissected
tissues and of limited DNA input. Second, this study provides the first detailed examination of 5mC
patterns in gonadectomy-induced adrenocortical neoplasms. Finally, this study provides the first
evaluation of 5mC and 5hmC in maturing motor neurons and provides the first evidence of an important
role for the Tet demethylation machinery in normal motor neuron maturation.
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CHAPTER 2: LASER CAPTURE MICRODISSECTION-REDUCED REPRESENTATION BISULFITE
SEQUENCING (LCM-RRBS) MAPS CHANGES IN DNA METHYLATION ASSOCIATED WITH
GONADECTOMY-INDUCED ADRENOCORTICAL NEOPLASIA IN THE MOUSE
Published in Nucleic Acids Research (2013).
ABSTRACT
DNA methylation is a mechanism for long-term transcriptional regulation and is required for
normal cellular differentiation. Failure to properly establish or maintain DNA methylation patterns leads to
cell dysfunction and diseases such as cancer. Identifying DNA methylation signatures in complex tissues
can be challenging due to inaccurate cell enrichment methods and low DNA yields. We have developed a
technique called Laser Capture Microdissection-Reduced Representation Bisulfite Sequencing (LCMRRBS) for the multiplexed interrogation of the DNA methylation status of CpG Islands and promoters.
LCM-RRBS accurately and reproducibly profiles genome-wide methylation of DNA extracted from
microdissected fresh frozen or formalin-fixed paraffin-embedded tissue samples. To demonstrate the
utility of LCM-RRBS, we characterized changes in DNA methylation associated with gonadectomyinduced adrenocortical neoplasia in the mouse. Compared to adjacent normal tissue, the adrenocortical
tumors showed reproducible gains and losses of DNA methylation at genes involved in cell differentiation
and organ development. LCM-RRBS is a rapid, cost-effective, and sensitive technique for analyzing DNA
methylation in heterogeneous tissues and will facilitate the investigation of DNA methylation in cancer and
organ development.
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INTRODUCTION
DNA methylation has long been recognized to play a role in normal cellular differentiation and
development. Methylation most often occurs at the cytosine of a cytosine-guanine dinucleotide (CpG) and
acts to down-regulate gene expression (Bird and Wolffe 1999). Disruption of the DNA methylation
machinery can lead to imprinting disorders (Robertson 2005), repeat-instability disease (Kumari and
Usdin 2009), and neurological defects (Chahrour et al. 2008; Jin et al. 2008).
DNA methylation has been shown to play an important role in cancer progression. Tumors often
display a global loss of methylation, or hypomethylation, at repetitive elements, which is thought to
destabilize the genome through transposon-mediated rearrangements (Goelz et al. 1985; Wilson et al.
2007), activate growth promoting oncogenes (Wilson et al. 2007), and cause de-differentiation through
the loss of imprinting (Reik and Lewis 2005). An abnormal gain of methylation, or hypermethylation, at
gene regulatory elements also contributes to tumorigenesis by silencing tumor suppressor genes involved
in DNA damage repair, cell cycle control and other processes (Jones and Baylin 2002). This aberrant
methylation may be due, at least in part, to recurring mutations in genes that are involved in epigenetic
regulation (Stratton 2011; Ryan and Bernstein 2012), such as DNA methyltransferases, which are
commonly mutated in acute myeloid leukemia (Ley et al. 2010), and chromatin remodeling enzymes,
which are frequently mutated in renal carcinomas and pancreatic neuroendocrine tumors (Dalgliesh et al.
2010; Jiao et al. 2011).
Accurate analysis of DNA methylation is complicated by the heterogeneous nature of normal and
diseased tissues. Normal tissues contain cells at different stages of differentiation/maturity. Tumors also
consist of histologically diverse cell types (Weinberg 2007; Shackleton et al. 2009) and display intratumor
heterogeneity in gene expression (Dalerba et al. 2011), genotype (Navin et al. 2010; Navin et al. 2011),
and metastatic and proliferative potential (Fidler et al. 1979; Heppner 1984). Therefore, the analysis of
gross tumor samples often obscures the diverse cell types that comprise the entire tumor (Michor and
Polyak 2010). To assess cell type specific DNA methylation of complex tissues, cell isolation techniques
must be used. Laser capture microdissection (LCM) has enabled researchers to separate specific cell
types from heterogeneous tissues (Espina et al. 2006). DNA yields from such samples, however, are too
small to use with current methods for genome-wide DNA methylation analysis. Moreover, clinical samples
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are typically fixed in formalin and embedded in paraffin, further compromising DNA quality. For these
reasons, the genome-wide mapping of DNA methylation in LCM samples has not been previously
demonstrated.
Current DNA methylation analysis methods are limited by the number of loci interrogated,
quantity and quality of DNA input required, and sample throughput (Laird 2010b). Methods that function
on a very small number of cells interrogate only a few genomic loci and are challenging to implement
(Dietrich et al. 2009; Herrmann et al. 2011). Furthermore, few methods function on clinical samples that
are formalin-fixed and paraffin-embedded (FFPE) (Dietrich et al. 2009). Genome-wide DNA methylation
methods are limited by the input of DNA. Affinity enrichment techniques like MeDIP-Seq (Taiwo et al.
2012), MDB-seq (Serre et al. 2010), MethylCap-seq (Brinkman et al. 2010) require 0.16 – 5 µg of DNA
input and are limited to a 150- to 200-bp resolution. Other global methods, like CHARM (Irizarry et al.
2008) and padlock probes (Ball et al. 2009; Diep et al. 2012) also require large DNA inputs. MethylC-seq,
the only truly whole genome approach (Lister et al. 2009), is prohibitively expensive when many samples
need to be analyzed. Reduced Representation Bisulfite Sequencing (RRBS) can map genome-wide DNA
methylation of limited DNA samples (Smith et al. 2012), but has not been demonstrated to function on
small amounts of DNA recovered from FFPE samples or on samples collected by LCM.
Here, we describe a new technique termed Laser Capture Microdissection-Reduced
Representation Bisulfite Sequencing (LCM-RRBS) that can interrogate genome-wide DNA methylation
patterns in samples collected from complex heterogeneous tissues. As a proof of principle, we have used
LCM-RRBS to analyze global DNA methylation changes associated with adrenocortical neoplasia in the
mouse. In response to gonadectomy (GDX) and the ensuing rise in serum gonadotropin levels, sex
steroid-producing neoplasms accumulate in the subcapsular region of the adrenal cortex of certain strains
of mice, including DBA/2J (Bielinska et al. 2006b). This phenomenon is thought to reflect gonadotropininduced metaplasia of stem/progenitor cells in the adrenal cortex, although the term neoplasia is used
more often than metaplasia to describe the process (Bielinska et al. 2006b).The molecular basis of GDXinduced adrenocortical neoplasia is unknown (Bernichtein et al. 2008b; Krachulec et al. 2012), but it has
been hypothesized that DNA methylation and other epigenetic modifications may impact the phenotypic
plasticity of adrenocortical stem/progenitor cells allowing them to respond to the rise in circulating

24

gonadotropins (Bielinska et al. 2009). GDX-induced adrenocortical neoplasia in the mouse is an ideal
phenomenon to study using LCM-RRBS because of the limited amounts of tissue that can be collected.

RESULTS
LCM-RRBS
Reduced Representation Bisulfite Sequencing (RRBS) is an established methylation analysis
method that can interrogate most CGIs and promoters across the entire genome. Current RRBS
protocols however, do not allow for multiplexing and have not been demonstrated on samples isolated by
LCM. Furthermore, although RRBS has been used to analyze small amounts of high quality DNA (Smith
et al. 2012), it has not been applied to less than 1 µg of DNA extracted from formalin-fixed paraffinembedded (FFPE) samples (Gu et al. 2010), the most common method used to preserve clinical tissue
samples. We therefore sought to develop a method to analyze small amounts (1 ng) of DNA from laser
capture microdissected samples and from FFPE-preserved samples and to interrogate multiple samples
in parallel.
Our protocol removes most clean-up steps, which ensures DNA samples are not lost, and
leverages the capabilities of Illumina indexing to pool samples prior to size selection and sequencing,
thus dramatically increasing the number of samples that can be processed in parallel (Figure 2.1). LCMRRBS digests genomic DNA with MspI to create fragments with a 5` CpG end. Digested fragments are
blunted, adenylated, and ligated with methylated sequencing adapters then column purified to remove
excess adapters. To convert the epigenetic methylation mark into a genetic mark that can be read
through genomic sequencing, adapter-ligated fragments are treated with bisulfite. At this stage, converted
DNA is amplified with a low-cycle PCR to introduce sample-specific indexes. Once each sample is
‘indexed,’ samples are pooled prior to gel electrophoreses and the isolation of 40-220 base pair
fragments. The purified, pooled library is PCR enriched using universal primers and sequenced on the
Illumina platform to generate 42 base pair reads. Using our modified method, we can interrogate CpGs
genome-wide from laser capture microdissected samples freshly frozen or previously preserved through
formalin-fixing and paraffin-embedding.
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LCM-RRBS accurately measures genome-wide DNA methylation of fresh frozen and formalin-fixed
paraffin-embedded samples
To evaluate the performance of LCM-RRBS, we benchmarked it against RRBS. Using 1 ng and
400 ng for LCM-RRBS and RRBS, respectively, we compared the genome-wide DNA methylation status
of DNA isolated from human blood leukocytes. We did not do LCM on the 1 ng of purified DNA; instead,
we only applied the downstream library preparation of the LCM-RRBS protocol (Figure 2.1). LCM-RRBS
was able to interrogate >75% of CGIs and >65% of gene promoters, results that were similar to those
obtained by RRBS (Figure 2.S1). LCM-RRBS was able to accurately measure the DNA methylation levels
of CGIs and core promoters (Figure 2.2A) as well as individual CpG dinucleotides (Figure 2.S2).
Increasing the required coverage for each CpG considered for CGI methylation did not significantly alter
the concordance between RRBS and LCM-RRBS (Figure 2.S3). For CGIs (n = 18,448) and promoters (n
= 8,500) having at least 50 methylation measurements, we observed a Pearson correlation of 0.98 and
0.94, respectively, between 1 ng and 400 ng (Figure 2.2A). Most CGIs are either highly methylated (80100%) or highly unmethylated (0-20%). We therefore sought to test how well LCM-RRBS could call a CGI
as methylated or unmethylated. For CGIs with at least 50 high-quality CpG measurements, LCM-RRBS
identified methylated CGIs with 91% sensitivity and 99% specificity and unmethylated CGIs with 97%
sensitivity and 94% specificity when compared to the RRBS dataset. We therefore conclude that LCMRRBS functions on as little as 1 ng of genomic DNA, interrogates most CGIs and promoters, and is very
accurate.
Human clinical samples are usually stored as either fresh frozen or FFPE specimens. Mapping
DNA methylation in the latter, however, can be challenging because formalin fixation degrades DNA.
Most DNA methylation techniques that have been used on FFPE samples require greater than 1 µg of
DNA or can only interrogate a few loci. To validate the reproducibility of LCM-RRBS and demonstrate its
universal clinical applicability, we performed methylation profiling on 1 ng samples of DNA from a primary
endometrial carcinoma, half of which was fresh frozen and the remainder which was formalin-fixed and
paraffin-embedded. Methylation of CGIs and promoters was highly concordant between fresh frozen and
FFPE samples (Pearson correlation 0.98 and 0.97, respectively; Figure 2.2B). CGI and promoter
methylation correlated strongly between FFPE technical replicates (Pearson correlation 0.97 and 0.95,
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respectively; Figure 2.S4). We also observed high concordance across individual CpGs between fresh
frozen and FFPE tumor samples with a Pearson correlation of 0.96 (Figure 2.S2). LCM-RRBS, therefore,
can accurately interrogate genome-wide methylation of 1 ng extracted from FFPE samples.

LCM-RRBS is robust across fresh frozen and formalin-fixed paraffin-embedded laser capture
microdissected samples
In situ analysis of DNA methylation is challenging due to the heterogeneous nature of complex
tissues. In order to interrogate only cells of interest in biological and clinical samples, LCM techniques
must be used to enrich for a specific cell type. Current genome-wide DNA methylation methods, however,
have not been demonstrated to function on LCM-collected samples. We therefore set out to evaluate the
performance of LCM-RRBS on fresh frozen and FFPE samples collected by LCM.
Because the cellular architecture of a normal liver is homogeneous, the methylation state should
be very similar throughout the organ. Thus, the liver serves as the ideal tissue for benchmarking the LCMRRBS method against the RRBS gold standard, since each microdissected region should have a very
similar methylation pattern to that of the bulk tissue. We harvested the liver of C57BL/6J mice and
prepared the liver using standard preservation techniques. Separate regions of the liver were either
directly snap frozen, preserved in Tissue-Tek O.C.T. compound and then snap frozen, or preserved using
formalin-fixation and paraffin-embedding. Bulk DNA was extracted from the snap frozen sample and used
for downstream RRBS analysis. To determine whether the process of LCM alters the methylation of DNA
2

and to assess the lower limits of LCM-RRBS, we applied LCM-RRBS to samples collected from 20 mm ,
2

2

2

10 mm , 5 mm , and 2 mm of the fresh frozen and FFPE mouse liver and compared the DNA
methylation patterns to those determined by performing RRBS on 400 ng of DNA extracted from the bulk
fresh frozen liver tissue. As observed with 1 ng of DNA, most CGIs and promoters were represented even
2

when only 2 mm of tissue was collected (Figure 2.S5). Furthermore, CGI (mean Pearson = 0.98) and
promoter (mean Pearson = 0.96) methylation showed high concordance across all fresh frozen samples
2

(Figure 2.3A) when compared to 400 ng of DNA. For samples collected from 2 mm of microdissected
tissue, LCM-RRBS identified unmethylated (0-20%) CGIs with 88% sensitivity and 99% specificity and
methylated (80-100%) CGIs with 99% specificity and 87% sensitivity. While the interrogation of DNA
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2

2

methylation of 2 mm of fresh frozen tissue was robust, 20 mm of FFPE tissue was required for accurate
2

analysis. Using 20 mm of FFPE starting material, LCM-RRBS showed 79% sensitivity and 99%
specificity for calling unmethylated (0-20%) CGIs and 99% sensitivity and 78% specificity for calling
methylated (80-100%) CGIs with a Pearson correlation of 0.95 (Figure 2.3B). Samples collected from less
2

than 20 mm of FFPE tissue, however, showed poor CGI, promoter, and CpG correlations as compared
to 400 ng (data not shown). We conclude that the process of LCM does not alter DNA methylation and
2

that LCM-RRBS accurately determines methylation patterns from as little as 2 mm of fresh frozen tissue.
2

FFPE tissue is more problematic requiring an area of at least 20 mm to achieve acceptable, but not
exceptional performance.

Evaluation of PCR Bias
PCR amplification of small amounts of bisulfite-treated DNA can result in PCR bias and
inaccurate DNA methylation calling (Warnecke et al. 1997). In DNA samples obtained from females, the X
chromosome serves as a good internal control for assessing PCR bias, since X inactivation methylates
one copy of the X chromosome at most loci. To determine if LCM-RRBS suffers from PCR bias, we
analyzed the fraction of molecules that were methylated at loci known to be affected by X inactivation.
As expected, the majority (>70%) of CGIs on the X chromosome showed an intermediate level (30-70%)
2

of DNA methylation across all fresh frozen samples and the 20 mm FFPE sample (Figure 2.S6),
demonstrating that LCM-RRBS shows little PCR bias. We conclude that LCM-RRBS shows little PCR
2

2

bias across 2 mm of fresh frozen tissue and 20 mm of FFPE tissue.

Analysis of GDX-induced adrenocortical neoplasia in the mouse using LCM-RRBS
To demonstrate the utility of LCM-RRBS in a biological setting, we applied the method to analyze
the DNA methylation of neoplasms that arise in the adrenal cortex of DBA/2J mice after GDX. Although
genetic factors have been identified that influence susceptibility to GDX (Bernichtein et al. 2008b;
Krachulec et al. 2012), little is known about the role DNA methylation plays in the formation of GDXinduced neoplasia. Molecular characterization is further complicated because mice adrenal glands are
2

only 0.1 cm in size and neoplasms arise among normal tissues requiring LCM enrichment methods for
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tissue isolation. We therefore applied LCM-RRBS to neoplastic and adjacent normal mouse adrenal
tissues (Figure 2.4).
In one multiplexed experiment, we interrogated the methylation status of >13,000 promoters and
>13,000 CGIs of 6 tissue samples (3 neoplastic and 3 normal representing 3 different mice) across an
average of >800,000 CpGs per sample (Figure 2.4 and Table 2.S1). Using a threshold difference of at
least 10%, 37 promoters were significantly hypomethylated and 8 promoters were significantly
hypermethylated (P < 0.05, FDR adjusted; Table 2.1 and Table 2.S2) in the neoplasms compared to
adjacent normal tissue. Many of the top hypo- and hypermethylated genes have been implicated in cell
fate determination and differentiation, including adrenocortical formation (Tinagl1), gonad development
(Foxs1, Wdr63, Tmem184a), pancreas development (Nsmce1), kidney development (Hoxc10, Dpep1),
prostate development (Il17rc, Ano7), and muscle and skeletal development (Myo18b, Trim63, Lmod3,
Meox1). The observed methylation changes suggest the neoplastic tissue may arise due to aberrant gene
expression of genes normally silent in adrenocortical cells or the silencing of adrenal-specific markers. To
validate our findings, we performed bisulfite-specific polymerase chain reaction (BSP) followed by
sequencing of 3 hypomethylated promoters and 1 hypermethylated promoter on neoplastic and normal
tissues isolated by LCM. For all promoters tested, BSP showed a significant difference (Fisher’s exact
-15

test, P < 10 ) in DNA methylation between the neoplasia and normal tissue as predicted by LCM-RRBS
(Figure 2.5). Taken together, these results demonstrate that LCM-RRBS can identify differentially
methylated genes in a complex tissue and reveal functionally relevant epigenetic effects.

DISCUSSION
Current DNA methylation mapping techniques are limited by input and the number of loci
interrogated. RRBS, a genome-wide DNA methylation mapping technique, was recently shown to function
on 0.5 to 10 ng of genomic DNA isolated from mouse embryos (Smith et al. 2012). RRBS, however, has
not been demonstrated to function on LCM samples collected from FFPE tissue nor is it amenable to
large scale sample processing. We have developed a new method, LCM-RRBS, which can accurately
profile genome-wide DNA methylation of many LCM samples in parallel at single base pair resolution.
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Our method can be implemented in 3-4 days, and the bulk of the protocol can be automated for
high-throughput 96-well experiments. While traditional RRBS requires each processed sample to undergo
gel extraction, a laborious process when processing more than a few samples, our method pools all
samples together prior to gel extraction, reducing the required number of gel extractions to one. Thus, a
large number of samples can be easily processed at a single time. Furthermore, because high DNA loss
results from gel extraction, pooling samples prior to gel extraction allows the use of low (1 ng) DNA
inputs.
The LCM-RRBS protocol affords a significant reduction in sequencing costs compared to whole
genome bisulfite sequencing. We typically collect 1.5 gigabases (GB) per sample, which is considerably
less than the ~60 GB needed for 20x coverage of a whole genome bisulfite library. The sequencing cost
per sample can be reduced further if fewer CpGs are interrogated. For example, if a smaller size fraction
is isolated during gel extraction, only about 0.75 GB are required per sample.
We found that although formalin-fixation and paraffin-embedding does not alter DNA methylation
2

per se, at least 20 mm of tissue must be isolated for accurate DNA methylation profiling. We were able to
2

2

2

create LCM-RRBS libraries from 10 mm , 5 mm , and 2 mm of FFPE tissue and obtained similar
numbers of sequencing reads as with fresh frozen samples, but overall mapping quality was very low
(~30% aligned) in the FFPE samples, precluding an accurate analysis of DNA methylation. On the other
2

hand, LCM-RRBS generated high quality methylation maps from 2 mm of microdissected fresh frozen
tissue, as demonstrated by our analysis of mouse liver.
To demonstrate the utility of LCM-RRBS, we analyzed the DNA methylation patterns of GDX2

induced adrenocortical neoplasms using an average of 5.5 mm of fresh frozen tissue. We hypothesized
that aberrant DNA methylation changes could be involved in the formation of these neoplastic tissues.
Indeed, recent studies have shown that altered DNA methylation can redirect cell fate in endocrine
tissues (Dhawan et al. 2011a). Conditional mutagenesis of the mouse Dnmt1 gene, which encodes the
maintenance DNA methyltransferase, converts insulin-producing pancreatic β-cells into glucagonproducing α-cells (Dhawan et al. 2011a). It is thought that because of a common developmental origin, βand α-cells share general epigenetic programs that provide a compatible environment for cell fate
conversions (Akerman et al. 2011). GDX-induced adrenocortical neoplasia may be another example of
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DNA methylation-regulated cell fate conversion in an endocrine tissue; in this case, adrenocorticoidproducing cells become sex-steroid producing cells (Bielinska et al. 2003b; Bielinska et al. 2005; Johnsen
et al. 2006b). The changes in DNA methylation we observe around the transcription start site (TSS)
could lead to changes in gene expression (Brenet et al. 2011; Hartung et al. 2012). Several of the genes
we found to be differentially methylated in GDX-induced adrenocortical neoplasms have established roles
in adrenocortical or gonadal development. For example, Tinagl1, a gene implicated in adrenal zonation
(Mukai et al. 2003; Li et al. 2007), showed a gain in DNA methylation, which could lead to downregulation. Wdr63, Foxs1, and Tmem184a, genes involved in gonadal development (Svingen et al. 2007;
Best et al. 2008; Bonilla and Xu 2008; Sato et al. 2008), showed a loss of DNA methylation, which could
lead to the aberrant expression of these gonadal-like markers in the adrenal cortex. Furthermore, Srd5a3,
a gene involved in the biosynthesis of the potent androgen 5α-dihydrotestosterone (Uemura et al. 2008),
showed a loss of DNA methylation, which could enhance the ectopic production of sex steroids in the
adrenal gland (Payne and Hales 2004). Future studies will explore the role of these methylation changes
in the pathogenesis of GDX-induced adrenocortical neoplasia.
In conclusion, LCM-RRBS is a robust, cost-effective method for the DNA methylation analysis of
heterogeneous tissues. This technique allows the study of tumor evolution and epigenetic heterogeneity
in situ of less than 1 ng (~150 cells) and can also be applied to investigate the role of DNA methylation in
cell fate specification during tissue development. LCM-RRBS is an important milestone toward highly
parallel in situ analysis of single cells. We anticipate that this protocol will greatly facilitate the analysis of
any sample that contains multiple cell types.
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MATERIALS AND METHODS

Experimental mice
Procedures involving mice were approved by an institutional committee for laboratory animal care
and were conducted in accordance with NIH guidelines for the care and use of experimental animals.
C57BL/6J and DBA/2J mice were purchased from Jackson Laboratories (Bar Harbor, ME). Mice were
anesthetized and ovariectomized at 3-4 weeks of age (Bielinska et al. 2005).

DNA extraction
Human tumor specimens were collected under an Institutional Review Board (IRB)-approved
protocol. Immediately after surgery, a human endometrial tumor was divided in half. One half was fresh
frozen while the other was formalin-fixed and paraffin-embedded (FFPE). 50 mg of fresh frozen
endometrial tumor was cut into small pieces with a sterile scalpel blade and DNA extracted using the
Maxwell 16 Tissue DNA Purification Kit (AS1030, Promega). The formalin-fixed paraffin-embedded
2

preserved portion was cut into 6-µm sections onto microscope slides. Four 4 mm slices were scratched
off the slide with a sterile scalpel blade, combined in 80 µl buffer and proteinase K (740901.50, Clontech),
and incubated overnight at 65°C. Liver tissue was harvested from C57BL/6J mice and divided in half. One
half was preserved in Tissue-tek optimal cutting temperature (O.C.T.) compound (25608-930, VWR) and
snap frozen, while the other half was formalin-fixed and paraffin-embedded for downstream bulk DNA
extraction and LCM. Fresh frozen, FFPE, and LCM samples were purified using NucleoSpin Tissue XS
columns (740901.5, Clontech) following the protocol for laser-microdissected tissue and eluted in 20 µl of
nuclease-free water. Genomic DNA was quantified using the Quant-it dsDNA High Sensitivity kit
(Invitrogen) and the Qubit fluorometer (Invitrogen).

Laser Capture Microdissection
Adrenal glands were harvested from mice 3 months after ovariectomy. Liver and adrenal
cryosections (10 µm) were collected on membrane slides (PEN-Membrane 2.0 µm; Leica) designed to
free the dissectate from the remainder of the tissue section. Adrenal tissue sections were fixed in
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acetone (5 sec, -20°C), stained with hematoxylin and eosin (H&E) or crystal violet, and dehydrated by
passage through successively higher concentrations of ethanol followed by xylene. FFPE livers sections
were deparaffinised and dehydrated using standard methods. LCM was performed using a Leica
LMD6000 microscope. Dissectates were collected in SDS/proteinase K for genomic DNA isolation
(740901.5, Clontech).

RRBS and LCM-RRBS
RRBS was performed on 400 ng of commercially purchased leukocyte genomic DNA (D1234148,
Amsbio) and genomic DNA extracted from a mouse liver as previously described (Gertz et al. 2011). For
LCM-RRBS, leukocyte genomic DNA (1 ng), extracted endometrial tumor genomic DNA (1 ng), and LCM
DNA samples were incubated overnight at 37°C with 20 U of the methylation insensitive restriction
enzyme MspI (R0106S, NEB) and 2 µl of 10 x NEBuffer 2 in a 18 µl reaction. Without subsequent
purification, fragment ends were filled in and an adenosine added with 10 U of Klenow Fragment (3` à 5`
-

exo , M0212L, NEB), 0.04 mM dGTP, 0.04 mM dCTP, 0.4 mM dATP, and 1x NEB Buffer 2 in a final
volume of 22.4 µl. The reaction was incubated at 30°C for 20 min, 37°C for 20 min, and heat inactivated
at 75°C for 20 min. Pre-annealed methylated paired-end Illumina indexing adapters (Adap1:
ACACTCTTTCCCTACACGACGCTCTTCCGATCT, Adap2: PGATCGGAAGAGCACACGTCTGAACTCCAGTCAC; P = phosphate) at a concentration of 0.26 mM were
ligated overnight at 16°C to the ends of the DNA fragments using 1200 U of T4 DNA Ligase (M0202L,
NEB) in 1x Ligase Buffer at a final volume of 28.9 µl. These adapter oligonucleotides are only
complementary at 13 bases which, after annealing, form a “Y” structure. Because excess adapters
prevent the complete conversion of CpGs at the MspI digestion site, adapter-ligated fragments are
purified using MinElute columns (Qiagen) and eluted twice with 11 µl of warm EB buffer. The purified
products were treated using the EZ DNA Methylation Gold Kit (D5005, Zymo). Samples were eluted in 11
µl of M-Elution buffer. To incorporate the sample-specific index, 3 µl of each bisulfite treated sample was
amplified in triplicate with 0.2 µM of indexed primers (PCR1:
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCT; PCR2:
CAAGCAGAAGACGGCATACGAGATNNNNNGTGACTGGAGTTCAGACGTGTGCTCTTCCGA,
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N=index), 5 U of Platinum Taq Polymerase (10966-034, Invitrogen), 1x PCR buffer, 2 mM MgCl2, 0.5 M
betaine (B0300, Sigma), 1 mM dNTP, in a 10 µl reaction using the following cycling conditions: 98°C for 2
min, 12 cycles of 98°C for 30 sec and 65°C for 2 min. All PCR products and replicates were pooled and
analyzed by electrophoresis on a 3% 1X Tris-acetate-EDTA (TAE) NuSieve agarose gel (50090, Lonza)
using a voltage of 5 V/cm until the blue loading dye was 6-7 cm away from the loading well. Fragments
between 150 bp and 350 bp were extracted and purified using MinElute columns (Qiagen) and 15 µl of
warmed EB buffer. Prior to final library PCR enrichment, the minimum cycle number must be determined
to ensure no PCR bias. Using 2 µl of eluted product and 0.2 µM universal primers (Pool1:
CAAGCAGAAGACGGCATACGAGAT, Pool2: AATGATACGGCGACCACCGAGATCT), multiple PCR
reactions with a final volume of 50 µl are set up using the previous conditions but varying the cycle
number from 10 – 16 cycles. 10 µl of each PCR product is analyzed through electrophoresis on a 4-20%
Precast TBE gel (3450059, BioRad) and stained with Sybr Gold (S-11494, Invitrogen) for 15 min and
imaged. In order to minimize PCR bias, the final PCR library is amplified in quadruplicate using the
previous PCR conditions and the minimum cycle number (typically ~14) that shows amplification only
within the 150-350 bp range on the Sybr Gold stained TBE gel. The four replicates are pooled and gel
extracted as previously mentioned to remove remaining adapter dimers and primers, then purified, and
sequenced on Illumina HiSeq 2000 machines.

Bisulfite-specific PCR
Neoplastic and adjacent normal mouse adrenocortical tissue was collected and bisulfite treated
using the EZ DNA Methylation-Direct kit following the manufacturer’s instructions for LCM samples eluting
with 15 µl of Nuclease-free water (D5020, Zymo). Bisulfite-specific PCR primers were designed using
MethPrimer (http://www.urogene.org/methprimer/). To amplify the promoter regions of interest, 2 µl of
bisulfite-treated DNA was combined with 2.5 U of Jumpstart Taq (Sigma), 1x PCR buffer, 1 M betaine
(B0300, Sigma), 0.2 mM dNTP, and 0.4 µM of each primer in a total reaction volume of 25 µl. The
reaction was incubated at 95°C for 5 min, followed by 5 cycles of 94°C for 30 sec, 60°C for 30 sec, and
72°C for 90 sec, followed by 5 cycles of 94°C for 30 sec, 55°C for 30 sec, and 72°C for 90 sec, followed
by 30-33 cycles of 94°C for 30 sec, 50°C for 30 sec, and 72°C for 90 sec, followed by 72°C for 5 min.

35

PCR products were prepared for sequencing on the MiSeq following the manufacturer’s protocol
(Illumina).

Sequence alignment and methylation calling
All analysis was performed using the February 2009 (GrCh37/hg19) build of the human genome
and the July 2007 (NCBI37/mm9) build of the mouse genome. On average 25 million single-end 42-bp
raw high quality reads per sample were either aligned to the cytosine-poor strand reference using the
bisulfite mode of MAQ (Li et al. 2008a) or aligned to the reduced reference using RRBSMAP (Xi et al.
2012) filtering against reads that contain adapter sequence. Reads that showed less than 90% bisulfite
conversion (~1 unconverted non-CpG cytosine per read) were filtered to remove those that resulted from
incomplete bisulfite converted molecules. Aligned reads with a mapping quality of zero were also
discarded. The resulting high quality uniquely mapped reads were used for methylation calling. We
identified the genomic coordinates of all CpGs in the reference sequence and assessed percent DNA
methylation by calculating the fraction of reads that had an unconverted cytosine at the CpG position
relative to the total reads. We required that each read have either a “TG” or “CG” dinucleotide at the
expected CpG coordinate to be considered for analysis.

Genomic feature annotation and statistical analysis
Cytosine methylation levels were determined for two classes of genomic features downloaded
from the UCSC genome browser (Rhead et al. 2010). CpG Islands (CGIs) were defined as a region
greater than 200 base pairs with a GC content of 50% or greater and observed-to-expected ratio of CG
dinucleotides greater than 0.6 (Gardiner-Garden and Frommer 1987). Promoters were defined as a 2 kb
region centered on the annotated transcription start site of RefSeq genes (Pruitt et al. 2012). For LCMRRBS, RRBS, fresh frozen, and FFPE comparisons, only genomic features with at least 100 methylation
measurements in each pairwise comparison were considered for analysis.
To identify differentially methylated promoters in adrenocortical neoplasia and normal samples,
the DNA methylation status of all CpGs within a 2 kb region of all RefSeq annotated transcription start
sites were compared. Those promoters with at least 50 methylation measurements that showed greater
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than 10% methylation difference were considered for statistical analysis. Promoters were considered
statistically significant with a P < 0.05 using Student’s t-test after p-values were adjusted using a falsediscovery rate (FDR) of 5%. Statistical significance across bisulfite-specific PCR samples was determined
using the Fisher’s exact test. All statistical analysis was performed using R.

Data Release
The DNA methylation data generated for this study can be found under the NCBI Gene
Expression Omnibus (GEO) accession number GSE45361. DNA methylation and raw sequence data are
also publically available at the Center for Genome Sciences (www.cgs.wustl.edu/~maxim/).
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FIGURE 2.1

Figure 2.1 LCM-RRBS workflow. A complex tissue is dissected using LCM. Extracted DNA is digested
by the methylation insensitive enzyme MspI, end repaired, and ligated with methylated Illumina adapters.
After bisulfite conversion, each sample is ’barcoded’ by introducing a sample-specific index (shown as
green, blue, or violet boxes) through low cycle PCR. Samples are pooled and loaded onto a high
percentage gel for fragment separation and size selection. Using universal primers, the final library is
amplified and sequenced on the Illumina platform.
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FIGURE 2.2

Figure 2.2 LCM-RRBS is reproducible and robust across 1 ng extracted from bulk fresh frozen and
formalin-fixed paraffin embedded (FFPE) samples. CpG Island methylation (top panels) and the
methylation at 2 kb regions flanking the transcription start site (bottom panels) were compared between
(A) 1 ng (LCM-RRBS) and 400 ng of purified leukocyte genomic DNA (RRBS); and (B) 1 ng of FFPE
DNA and 1 ng of fresh frozen genomic DNA extracted from the same endometrial tumor (LCM-RRBS).
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FIGURE 2.3

Figure 2.3 LCM-RRBS is robust across microdissected samples collected from fresh frozen and
FFPE tissues. Fresh frozen and formalin-fixed paraffin-embedded (FFPE) mouse liver was collected for
2

DNA methylation profiling. LCM was used to collect tissue from areas ranging in size from 20 to 2 mm .
CpG Island methylation (top panels) and methylation at 2 kb regions flanking the transcription start site
(bottom panels) were compared between (A) fresh frozen samples (LCM-RRBS) and 400 ng of purified
mouse liver genomic DNA (RRBS); and (B) FFPE samples (LCM-RRBS) and 400 ng of purified mouse
liver genomic DNA (RRBS).
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FIGURE 2.4

Figure 2.4 DNA methylation profiling of GDX-induced adrenocortical neoplasms and adjacent
normal tissue using LCM-RRBS. The adrenal glands of 3 ovariectomized DBA/2J mice were fresh
frozen in Tissue-tek O.C.T. compound, cryosectioned, and stained. Shown are representative
cryosections pre- and post-LCM. Normal cells in the zona fasciculata (ZF) contain large lipid droplets that
are easily recognized. In contrast, neoplastic cells distort the normal adrenal zonal architecture and
contain relatively few lipid droplets. The microdissected normal tissue included zona glomerulosa and
zona fasciculata cells; care was taken to avoid dissection of X-zone (X), medulla (M), or capsule cells, as
these cell types have distinct developmental origins (Morohashi and Zubair 2011) and therefore may have
2

different epigenetic fingerprints. An average of 5.5 mm of neoplastic (red) and normal (green) tissue per
adrenal pair was collected and analyzed using LCM-RRBS.

41

FIGURE 2.5

Figure 2.5 Validation of differentially methylated promoters. The DNA methylation of one
hypermethylated and three hypomethylated promoters was interrogated by bisulfite-specific PCR (BSP)
and sequencing across enriched neoplastic and normal samples. All genes show a statistically significant
-15

difference (Fisher’s exact test, P < 10 ) in DNA methylation using bisulfite-specific PCR. Each colored
box represents an individual CpG dinucleotide within a 2 kb region centered around the transcription start
site. High (yellow), moderate (black), low (blue), and undetermined methylation levels are shown for each
CpG. The mean methylation of each region interrogated is shown to the right of each heatmap. The red
box indicates the region of the promoter that was interrogated by LCM-RRBS and BSP.
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TABLE 2.1

Table 2.1 Top hypermethylated and hypomethylated genes in GDX-induced adrenocortical
neoplasms of the mouse.
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SUPPLEMENTARY FIGURES AND TABLES
FIGURE 2.S1

Figure 2.S1 LCM-RRBS can interrogate the DNA methylation status of most CpG Islands and core
promoters. For all UCSC annotated CpG Islands and core promoters, defined as a 2 kb region centered
on the transcription start site, we determined the read coverage. Coverage is defined as the total number
of reads covering a CpG within a given genomic interval.
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FIGURE 2.S2

Figure 2.S2 LCM-RRBS is reproducible and robust at the CpG level across 1 ng of formalin-fixed
paraffin-embedded DNA. LCM-RRBS and RRBS were applied to 1 ng and 400 ng of commercially
purchased leukocyte genomic DNA, respectively, and showed a high concordance across individual
CpGs (Pearson, 0.93). LCM-RRBS was applied to 1 ng of DNA extracted from fresh frozen or formalinfixed paraffin-embedded endometrial tumor tissue. CpG methylation was highly concordant between fresh
frozen and FFPE samples and FFPE technical replicates (Pearson, 0.96 and 0.94, respectively). Only
CpGs covered by at least 20 reads in each sample were considered.
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FIGURE 2.S3

Figure 2.S3 Increasing individual CpG coverage does not significantly alter the concordance of
CGI methylation between data collected by RRBS (400 ng) and LCM-RRBS (1 ng). The methylation
of each CGI was calculated by determining the mean methylation of only those CpGs within the region
that were covered by at least 10 reads in both datasets. Only CGIs that were covered by a total of 100
reads were considered for concordance analysis.
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FIGURE 2.S4

Figure 2.S4. LCM-RRBS is reproducible and robust across 1 ng extracted from bulk FFPE
samples. CpG Island methylation (top panels) and the methylation at 2 kb regions flanking the
transcription start site (bottom panels) were compared between two technical replicates of 1 ng of FFPE
endometrial tumor DNA using LCM-RRBS.
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FIGURE 2.S5

Figure 2.S5 LCM-RRBS interrogates most CpG Islands and core promoters of liver mouse
samples collected by laser capture microdissection (LCM). For CpG Islands and core promoters,
defined as a 2 kb region centered on the RefSeq transcription start site, we determined the mean read
coverage of samples collected by LCM from fresh frozen and FFPE tissues. Coverage is defined as the
total number of reads covering a CpG within a given genomic interval.
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FIGURE 2.S6

Figure 2.S6 DNA methylation distribution of CpG Islands on chromosome X. The DNA methylation
status of all UCSC annotated CpG islands across the X chromosome was determined for 1 ng of fresh
frozen DNA extracted from bulk liver tissue and fresh frozen and FFPE samples collected by LCM to
assess the presence of PCR bias. Due to X-inactivation, we expect the majority of CpG Islands to be
moderately methylated (30-70%), as observed, confirming that LCM-RRBS is largely immune to PCR
2

2

bias down to 2 mm of fresh frozen and 20 mm of FFPE tissue.
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TABLE 2.S1
http://nar.oxfordjournals.org/content/suppl/2013/03/27/gkt230.DC1/nar-01911-met-h-2012-File009.xlsx
Table 2.S1 DNA Methylation of core promoters (2kb centered around the TSS) across normal and
neoplasia adrenocortical samples. Percent DNA methylation of annotated CpG Islands. ND: Not
determined. The URL address above contains a link to Table 2.1S.

TABLE 2.S2
http://nar.oxfordjournals.org/content/suppl/2013/03/27/gkt230.DC1/nar-01911-met-h-2012-File010.xlsx
Table 2.S2 Gene promoter DNA methylation analysis of normal and neoplasia tissue. Promoters are
defined as the regions within 1 kb upstream and downstream of the transcription start site. This table lists
the genes and respective DNA methylation levels for those that pasted multiple hypothesis corrections
(FDR adjusted). The URL address above contains a link to Table 2.2S.
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CHAPTER 3: NOVEL MARKERS OF GONADECTOMY-INDUCED ADRENOCROTICAL NEOPLASIA
IN THE MOUSE AND FERRET
In review at Molecular Cellular Endocrinology (2014).
ABSTRACT
Gonadectomy (GDX) induces sex steroid-producing adrenocortical tumors in certain mouse
strains and in the domestic ferret. Complementary approaches, including DNA methylation mapping and
microarray expression profiling, were used to identify novel genetic and epigenetic markers of GDXinduced adrenocortical neoplasia in female DBA/2J mice. Markers were validated using a combination of
laser capture microdissection, quantitative RT-PCR, in situ hybridization, and immunohistochemistry.
Two genes with hypomethylated promoters, Igfbp6 and Foxs1, were upregulated in post-GDX
adrenocortical neoplasms. The neoplastic cells also exhibited hypomethylation of the fetal adrenal
enhancer of Sf1, an epigenetic signature that typifies descendants of fetal adrenal cells. Expression
profiling demonstrated upregulation of gonadal-like genes, including Spinlw1, Insl3, and Foxl2, in GDXinduced adrenocortical tumors of the mouse. One of these markers, FOXL2, was detected in
adrenocortical tumor specimens from gonadectomized ferrets. These new markers may prove useful for
studies of steroidogenic cell development and for diagnostic testing.
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INTRODUCTION
Steroidogenic cells in the adrenal cortex and gonads arise from a common pool of progenitors in
the adrenogonadal primordia, but the mechanisms that determine whether a given precursor cell adopts
an adrenocortical or gonadal phenotype are not fully understood (Val et al. 2006; Hu et al. 2007;
Morohashi and Zubair 2011; Wood and Hammer 2011; Laufer et al. 2012; Shima et al. 2012; Simon and
Hammer 2012; Bandiera et al. 2013; Pihlajoki et al. 2013b; Wood et al. 2013). One experimentally
tractable model for the study of steroidogenic cell fate determination is gonadectomy (GDX)-induced
adrenocortical neoplasia. In response to GDX and the ensuing changes in serum hormone levels [↑
luteinizing hormone (LH), ↓ inhibins, etc.], sex steroid-producing tumors arise in the adrenal glands of
certain mouse strains and ferrets (Bielinska et al. 2005; Bielinska et al. 2006a; Johnsen et al. 2006a;
Bernichtein et al. 2007; Bernichtein et al. 2008a; Bernichtein et al. 2009; Doghman and Lalli 2009;
Beuschlein et al. 2012; Miller et al. 2013). This phenomenon is thought to reflect gonadotropin-induced
metaplasia of stem/progenitor cells in the adrenal capsule or cortex, although the term “neoplasia” is used
more often than “metaplasia” to describe the process (Bielinska et al. 2006a). The neoplastic tissue
resembles luteinized ovarian stroma and expresses gonadal-like differentiation markers, including LH
receptor (Lhcgr), anti-Müllerian hormone (Amh) and its receptor (Amhr2), inhibin-α (Inha), transcription
factors Gata4 and Wt1, and enzymes required for sex steroid biosynthesis (Cyp17a1, Cyp19a1)
(Bielinska et al. 2003a; Bielinska et al. 2005; Bielinska et al. 2006a; Johnsen et al. 2006a; Krachulec et al.
2012; Bandiera et al. 2013). Prototypical markers of adrenocortical cell differentiation, such as the ACTH
receptor (Mc2r) or corticoid biosynthetic enzymes (Cyp21, Cyp11b1, Cyp11b2), are not expressed in the
neoplastic tissue (Bielinska et al. 2003a; Bielinska et al. 2005; Bielinska et al. 2006a; Johnsen et al.
2006a).
The genetic basis of GDX-induced adrenocortical neoplasia has been investigated in the mouse.
Hypophysectomy, parabiosis, and transplantation experiments have shown that the adrenal glands of
susceptible strains of mice exhibit an inherent predisposition to develop tumors in response to
gonadotropin stimulation [reviewed in (Bielinska et al. 2005; Bielinska et al. 2006a)]. Linkage analysis of
crosses between susceptible (DBA/2J) and non-susceptible (C57Bl/6) inbred strains has established that
post-GDX adrenocortical neoplasia is a complex trait influenced by multiple genetic loci (Bernichtein et al.

52

2007; Bernichtein et al. 2008a; Bernichtein et al. 2009). Targeted mutagenesis of Gata4, a gene normally
expressed in gonadal but not adrenal steroidogenic cells of the adult mouse, attenuates post-GDX
adrenocortical tumor formation in susceptible strains (Krachulec et al. 2012), and transgenic expression
of Gata4 induces adrenocortical neoplasia in a non-susceptible strain (Chrusciel et al. 2013).
In addition to genetic factors, epigenetic changes such as DNA methylation may contribute to the
pathogenesis of GDX-induced adrenocortical neoplasia. Altered methylation of cytosine residues in CpG
dinucleotides has been shown to modulate gene expression and progenitor cell fate in various tissues,
including endocrine organs (Aranda et al. 2009; Hoivik et al. 2011). For example, conditional
mutagenesis of the mouse Dnmt1 gene, which encodes the maintenance DNA methyl-transferase,
causes reprogramming of pancreatic β-cells into α-cells (Akerman et al. 2011; Dhawan et al. 2011a). It
has been suggested that GDX-induced adrenocortical neoplasia may be another example of DNA
methylation-regulated cell fate interconversion in an endocrine tissue (Bielinska et al. 2009; Schillebeeckx
et al. 2013). According to this hypothesis, epigenetic alterations affect the phenotypic plasticity of
adrenocortical stem/progenitor cells, allowing them to respond to the hormonal changes associated with
GDX (Feinberg et al. 2006b; Bielinska et al. 2009).
The current study was undertaken to identify novel genetic and epigenetic markers of GDXinduced adrenocortical neoplasia, so as to gain a better foothold for investigations into the mechanistic
basis of tumorigenesis. Complementary approaches, including genome-wide DNA methylation mapping
and microarray expression profiling, were used to screen for genes that are hypomethylated and/or
overexpressed in post-GDX adrenocortical neoplasms of the mouse. Candidate genes were validated
using a combination of laser capture microdissection (LCM), quantitative RT-PCR (qRT-PCR), and in situ
hybridization or immunohistochemistry. One of the validated genes was found to be a marker of postGDX adrenocortical neoplasia in not only mice but also ferrets.
RESULTS AND DISCUSSION
Genes identified as hypomethylated by genome-wide analysis are upregulated in GDX-induced
adrenocortical neoplasms of the mouse
In a prior report, we used a highly sensitive method of global DNA methylation analysis, termed
LCM-RRBS, to identify gene promoters that are differentially methylated in neoplastic vs. normal
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adrenocortical tissue from ovariectomized DBA/2J mice (Schillebeeckx et al. 2013). We reasoned that
promoters that are hypomethylated in the neoplastic tissue could be novel markers of GDX-induced
adrenocortical tumorigenesis. In the current study, we subjected these hypomethylated candidate genes
to a series of validation studies. To be considered a bona fide marker of GDX-induced adrenocortical
neoplasia, we stipulated that three criteria had to be met: 1) qRT-PCR analysis of mRNA isolated from
whole adrenal glands had to show a significant increase in expression of the gene in gonadectomized vs.
intact mice, 2) qRT-PCR analysis of mRNA isolated by LCM had to show a significant increase in
expression of the gene in neoplastic vs. adjacent normal adrenocortical tissue, and 3) in situ hybridization
or immunohistochemistry of adrenal tissue from gonadectomized mice had to demonstrate expression in
the neoplastic cells. Of the 37 hypomethylated genes identified in the genome-wide screen, we assessed
the expression difference for 31 genes using whole adrenal qRT-PCR (criteria 1), 6 genes using LCM
qRT-PCR (criteria 2), and 5 genes using in situ staining or immunohistochemistry (criteria 3). Two
hypomethylated genes, Igfbp6 and Foxs1, fulfilled all three criteria (Figure 3.1A-F).
Igfbp6 encodes a member of a family of insulin-related growth factor binding proteins (IGFBPs),
which modulate the interaction of insulin-related growth factors (IGFs) with their cell surface receptors.
IGFBP6 differs from the other 5 members of the IGFBP family in that it has a 30- to 100-fold preferential
binding affinity for IGF2 over IGF1 (Bach et al. 1993). Both IGF2 and IGF1 impact the growth,
differentiation, and function of adrenocortical cells (Weber et al. 1999), and IGFBP6 has been shown to
inhibit the actions of IGF2 in experimental systems (Bach et al. 1994). Hormone-dependent Igfbp6
expression has been documented in somatic cells of the rodent ovary (Rohan et al. 1993). It is
conceivable that IGFBP6 produced in post-GDX adrenocortical neoplasms serves an insulator function by
blocking the activity of IGF2, thereby favoring gonadal-like differentiation over adrenocortical
differentiation.
Foxs1 (Fkhl18) encodes a forkhead-domain transcription factor that is expressed in Sertoli cells
and periendothelial cells of the developing mouse fetal testis (Sato et al. 2008). Male and female Foxs1
knockout mice are viable and fertile, but the mutant males accumulate blood in the fetal testis,
presumably due to apoptosis of periendothelial cells (Sato et al. 2008). Foxs1 is also expressed in
gonadal-like cells that accumulate in the adrenal subcapsule of Gata6
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flox/flox

; Sf1-cre mice (Pihlajoki et al.

2013a). In addition to gonadal(-like) cells, Foxs1 is expressed in neural crest derivatives (Heglind et al.
2005; Montelius et al. 2007); consistent with this notion, in situ hybridization showed strong Foxs1
expression in the neoplastic adrenocortical cells and weak expression in chromaffin cells of the adrenal
medulla (Figure 3.1E).
That only two of the hypomethylated genes identified in the original screen fulfilled all three
validation criteria is not surprising. Hypermethylation is correlated with increased gene expression, but
the relationship is not absolute. Whole adrenal qRT-PCR may not detect small, but significant,
expression differences. The small amounts of RNA isolated by LCM precluded qRT-PCR validation of a
large number of genes.

Locus-specific DNA methylation analysis of a fetal adrenal enhancer in GDX-induced
adrenocortical neoplasms
LCM-RRBS does not interrogate all methylated loci. To supplement the genome-wide screen, we
performed locus-specific DNA methylation analysis of an intronic enhancer of steroidogenic factor-1 (Sf1,
AdBP4, Nr5a1), a transcription factor that regulates steroidogenic cell differentiation in the adrenal cortex
and gonads (Buaas et al. 2012). The fetal adrenal enhancer (FAdE) of Sf1 (Zubair et al. 2006; Zubair et
al. 2008; Morohashi and Zubair 2011) is hypomethylated both in the fetal adrenal and adult adrenal cortex
(Hoivik et al. 2011; Hoivik et al. 2013). In contrast, the FAdE is hypermethylated in other tissue types,
including tissues that express Sf1 (ventromedial nucleus of the hypothalamus, pituitary gonadotropes)
and those that do not (pituitary nongonadotropes, liver) (Hoivik et al. 2011). The adrenal cortex of the
adult mouse is derived from fetal adrenal cells in which the FAdE was transiently active during
development (Zubair et al. 2008; Morohashi and Zubair 2011), implying that once demethylation has
occurred in the fetal adrenal, the methylation pattern is maintained during subsequent cell divisions and
conserved in the adult cortex. We hypothesized that the methylation status of the Sf1 FAdE in post-GDX
adrenocortical neoplastic cells could serve as an epigenetic marker for the neoplastic tissue. To assess
the DNA methylation status of the Sf1 FAdE, we performed bisulfite-specific PCR on tissue isolated by
LCM (Figure 3.2). Consistent with published reports (Hoivik et al. 2011; Hoivik et al. 2013), the FAdE was
hypermethylated in the liver and hypomethylated in both the adrenal X-zone [a remnant of the fetal
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adrenal (Morohashi and Zubair 2011)] and the adult adrenal cortex (zF + zG). Importantly, the FAdE was
also hypomethylated in post-GDX adrenocortical neoplasms.
To determine whether FAdE methylation status could distinguish the embryonic origin of the
neoplastic cells (fetal adrenal vs. ectopic ovarian cells), we measured FAdE methylation in whole ovary.
Ovarian tissue exhibited an intermediate level of FAdE methylation that was statistically greater than that
of adult adrenal cortex (P < 0.01) and X-zone (P < 0.005) but not that of post-GDX tumors (P = 0.085, not
significant). We conclude that GDX-induced tumor cells, like adjacent normal adrenocortical cells, carry
an epigenetic mark (FAdE hypomethylation) that typifies descendants of fetal adrenal cells; however, the
methylation status of this locus cannot exclude a gonadal origin for the neoplastic cells.

RNA expression profiling identifies novel markers of GDX-induced adrenocortical neoplasia in the
mouse
Since differential DNA methylation is only one of several mechanisms that can influence gene
expression, we performed microarray hybridization to screen for additional transcripts that are
upregulated during GDX-induced adrenocortical tumorigenesis. For this analysis we used mRNA isolated
from whole adrenal glands of ovariectomized vs. intact DBA/2J mice. We identified 89 and 38 genes that
were upregulated and downregulated, respectively, in adrenal glands from gonadectomized mice
(Supplemental Table 1). We hypothesized that the upregulated genes were enriched for markers of
gonadal tissue. To test this hypothesis, genes that were differentially expressed in the adrenal glands of
gonadectomized mice were compared to pooled GEO microarray data for different mouse tissues, using
an established algorithm (Chen et al. 2013). Enrichment analysis demonstrated that genes upregulated
in the adrenal glands of gonadectomized mice were more likely to be highly expressed in ovary (Figure
-8

-7

3.3A; P = 2.01 x 10 ) or testis (Figure 3.3B; P = 2.16 x 10 ) but not in the non-steroidogenic tissue brain
(Figure 3.3D; P = 0.90). Genes downregulated in the adrenal glands of gonadectomized mice were more
-4

likely to be highly expressed in the normal adrenal tissue (Figure 3.3C; P = 7.83 x 10 ) than in brain
(Figure 3.3E; P = 1.00). This systematic, transcriptomic comparison reinforces the longstanding tenet
that GDX induces the selective accumulation of gonadal-like cells in the adrenal glands of DBA/2J mice.
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Among the genes upregulated in the microarray analysis were gonadal-like markers known to be
expressed in post-GDX adrenocortical neoplasms, such as Cyp17a1 (460-fold), Lhcgr (43-fold), Inha (17fold), and Amhr2 (6.2- to 9.1-fold on different microarray probes) (Bielinska et al. 2006a). Two welldocumented markers of GDX-induced adrenocortical neoplasia, Gata4 and Amh (Bielinska et al. 2006a),
were not upregulated, underscoring the inherent limitations of microarray technology (each of these
genes was represented by a single probe on the microarray and showed a non-significant expression
change of ~0.5-fold). Two genes identified in the microarray screen, Spinlw1 and Insl3, were validated as
novel markers of GDX-induced adrenocortical neoplasia in the mouse, using the same rigorous criteria
described above (Figure 3.4A-E).
Spinlw1, which was upregulated 16- to 51-fold on different microarray probes, encodes EPPIN, a
serine protease inhibitor secreted by Sertoli cells and epididymal epithelial cells (O'Rand et al. 2011) but
not by cells of the ovary or uterus (Sivashanmugam et al. 2003; Silva et al. 2012). Thus, EPPIN is
generally considered to be a “male-specific” marker. Consistent with this notion, expression of Spinlw1
has been shown to be androgen-dependent (Denolet et al. 2006; Schauwaers et al. 2007; Willems et al.
2010; Silva et al. 2012).
Insl3, which was upregulated 50-fold on the microarray, encodes insulin-like 3, a hormone that is
secreted by fetal Leydig cells. INSL3 mediates the trans-abdominal phase of testicular descent (Ivell et
al. 2013), and loss-of-function mutations in Insl3 cause cryptorchidism (Ivell and Anand-Ivell 2011).
Additionally, INSL3 is constitutively secreted by adult Leydig cells and serves as a serum biomarker of
this cell type (Anand-Ivell et al. 2009), although the function of INSL3 in the adult testis remains unclear
(Ivell et al. 2013). Insl3 is also expressed in the ovary, particularly in theca interna cells of the maturing
follicle (Satchell et al. 2013), where it induces androgen production (Glister et al. 2013). It is conceivable
that serum levels of INSL3 could be a biomarker of post-GDX adrenocortical neoplasms, and future
experiments will explore this possibility.
Foxl2, a gene that was marginally upregulated (1.3-fold) in the microarray analysis, was found to
be another bona fide marker of GDX-induced adrenocortical neoplasia in the mouse (Figure 3.5A-F).
Foxl2 encodes a forkhead transcription factor that is expressed in granulosa and interstitial cells of the
ovary (Schmidt et al. 2004; Mork et al. 2012). Consequently, FOXL2 is generally considered to be a
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“female-specific” marker (Georges et al. 2013). Mice harboring null mutations in Foxl2 develop ovaries
that express testicular differentiation markers (Schmidt et al. 2004; Uda et al. 2004; Ottolenghi et al. 2005;
Garcia-Ortiz et al. 2009; Uhlenhaut et al. 2009). Of note, extracts of adrenal glands from nongonadectomized mice have been shown to contain FOXL2 mRNA and protein at levels 40-50 times lower
than extracts of ovary (Yang et al. 2010). The significance of this low level expression of Foxl2 in nonneoplastic adrenal glands is unclear.
None of these validated, gonadal-like genes showed evidence of differential methylation in the
LCM-RRBS analysis (Schillebeeckx et al. 2013). The degree of methylation of the Foxl2 promoter was
<1% in both neoplastic and normal tissue, and the degree of methylation of the Insl3 promoter was
comparable in neoplastic and normal tissue (13% vs. 16%; σ = 4.1 and σ = 5.3, respectively). Coverage
of the Spinlw1 promoter was inadequate for quantification of its methylation status.
In addition to gonadal-like markers, 3 mast cell enzyme genes, Cma1, Cma2, and Cpa3, were
upregulated (2.5- to 8.4-fold) in the adrenal glands of gonadectomized mice (Supplemental Table 1). This
finding is consistent with the well-documented phenomenon of mast cell infiltration of post-GDX
adrenocortical neoplasms (Kim et al. 1997; Bielinska et al. 2005).

FOXL2 is a marker of adrenocortical neoplasia in gonadectomized ferrets
Sex steroid-producing neoplasms arise in up to 20% of gonadectomized ferrets and are a major cause of
morbidity and mortality in this species (Bielinska et al. 2006a; Beuschlein et al. 2012). Immunostaining of
archival veterinary pathology specimens showed that FOXL2 is a marker of post-GDX adrenocortical
neoplasia in the ferret (Figure 3.6A-F; Figure 3.S1). The specimens were obtained from gonadectomized
ferrets with signs of ectopic sex steroid production (e.g., alopecia, vulvar hyperplasia, or stranguria) and
included examples of adrenocortical carcinoma, adenoma, and nodular hyperplasia. Several of the
specimens contained residual normal cortex, which served as a negative control (Figure 3.6A, C, E).
Nuclear FOXL2 immunoreactivity was detected in 50% of the specimens examined [4 of 10 cases of
adrenocortical carcinoma, 4 of 6 cases of adrenocortical adenoma, and 1 of 2 cases of nodular
hyperplasia]. FOXL2-positive tumors were seen in both female (Figure 3.6) and male (Figure 3.S1)
ferrets. Only a minority of the cells within a given tumor reacted with FOXL2 antibody (Figure 3.6D;
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Figure 3.S1). By comparison, nuclear GATA4 immunoreactivity has been observed in >90% of ferret
adrenocortical tumors (Peterson et al. 2004), and GATA4 antibody typically stains a higher percentage of
cells within a given tumor (Figure 3.6F).
We conclude that FOXL2 is a marker of GDX-induced adrenocortical tumors in not only the
mouse but also the ferret. This observation expands the list of genes known to be expressed in sex
steroidogenic adrenocortical neoplasms of the ferret (Schoemaker et al. 2002; Peterson et al. 2003;
Peterson et al. 2004; Bielinska et al. 2006a; Wagner et al. 2008; de Jong et al. 2013; de Jong et al. 2014).
The relatively low percentage of FOXL2 immunoreactive cells within ferret adrenocortical tumors may limit
the diagnostic utility of this marker. It remains to be determined whether the other markers of
adrenocortical neoplasia that emerged from our screens of gonadectomized mice are also markers of
tumorigenesis in ferrets.

Summary
Using complementary approaches, including DNA methylation analysis and microarray
expression profiling, we have identified novel epigenetic (Igfbp6, Foxs1) and genetic (Spinlw1, Insl3,
Foxl2) markers of GDX-induced adrenocortical neoplasia in the mouse. That both “male-specific”
(Spinlw1) and “female-specific” (Foxl2) markers were detected is noteworthy and implies that the
neoplasms exhibit mixed characteristics of male and female gonadal somatic cells. Such indeterminate
steroidogenic cell phenotypes have been reported in other experimental models (Heikkila et al. 2002; Val
et al. 2006). One of the markers, FOXL2, was observed in adrenocortical tumor specimens from
gonadectomized ferrets. These new markers may prove useful for studies of steroidogenic cell
development and for tumor classification.

Highlights
•

Igfbp6 & Foxs1 are hypomethylated and upregulated in murine post-GDX adrenocortical tumors.

•

The Sf1 FAdE is hypomethylated in murine post-GDX adrenocortical tumors.

•

Spinlw1, Insl3, & Foxl2 are upregulated in murine post-GDX adrenocortical tumors.

•

FOXL2 immunoreactivity is evident in adrenocortical tumors from gonadectomized ferrets.
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•

Post-GDX adrenocortical tumors exhibit properties of female and male gonadal cells.
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MATERIALS AND METHODS

Experimental animals
Procedures involving mice were approved by an institutional committee for laboratory animal care
and were conducted in accordance with NIH guidelines for the care and use of experimental animals.
DBA/2J mice were purchased from Jackson Laboratories (Bar Harbor, ME). Female mice were
anesthetized and gonadectomized at 3-4 weeks of age (Bielinska et al. 2005). We limited our analysis to
females because they develop post-GDX adrenocortical neoplasms more readily than their male
counterparts (Bielinska et al. 2006a; Beuschlein et al. 2012). Adrenal tissue was harvested for analysis 3
months later.

Isolation of neoplastic and normal tissue using LCM
Cryosections (10 µm) of adrenal glands from ovariectomized or intact mice were collected on
membrane slides (PEN-Membrane 2.0 µm; Leica), fixed in acetone (for collecting DNA) or ethanol (for
collecting RNA) at -20º C, stained with hematoxylin and eosin (H&E) or crystal violet, and then
dehydrated by passage through successively higher concentrations of ethanol followed by xylene
(Pihlajoki et al. 2013a; Schillebeeckx et al. 2013). LCM was used to isolate samples from GDX-induced
adrenocortical neoplasms, adjacent normal adrenocortical tissue [zona glomerulosa (zG) + zona
fasciculata (zF) cells], and the adrenal X-zone. Dissectates were collected in SDS/proteinase K for
genomic DNA isolation or in RNA extraction buffer (RNeasy Mini Kit, Qiagen, Valencia, CA).

Global and locus-specific DNA methylation analyses
DNA from neoplastic or normal adrenocortical tissue was subjected to genome-wide methylation
analysis using LCM-reduced representation bisulfite sequencing (LCM-RRBS) (Schillebeeckx et al.
2013). Locus-specific DNA methylation of the Sf1 enhancer locus was measured via bisulfite-specific
PCR and pyrosequencing as described previously (Schillebeeckx et al. 2013).
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Microarray expression profiling
RNA was isolated from whole adrenal glands of intact, virgin (n = 3) or ovariectomized (n = 3)
®

female DBA/2J mice using RNeasy Mini Kit (Qiagen, Valencia, CA), amplified using the TotalPrep RNA
amplification kit (Illumina, San Diego, CA), and hybridized on an Illumina Mouse6v2 oligonucleotide array.
Array hybridization was performed by the GTAC Microarray Core facility at Washington University
according to standard protocols. Probes with a hybridization signal less than signal background were
excluded from the analysis, leaving 15,066 probes. Probes that did not show at least a 2-fold change in
either direction were then excluded, leaving 628 probes (Table 3.S1). Finally, we determined statistical
significance using the Student’s t test and correcting for multiple hypothesis testing using the BenjaminiHochberg method, leaving a total of 127 probes (q-value < 0.05). Statistically significant upregulated (n =
89) and downregulated (n = 38) probes correspond to 85 and 36 genes, respectively (Table 3.S1).
Genes that were differentially expressed in adrenal glands from gonadectomized vs. intact mice
were compared to pooled Gene Expression Omnibus (GEO) data for different mouse tissues, using nonparametric statistical testing (Chen et al. 2013). Genes with a statistically significant expression
specificity (q-value < 0.01; Benjamini-Hochberg corrected) for adrenal, brain, ovary, or testis tissues were
considered to be tissue-specific (Table 3.S2). Enrichment for upregulated or downregulated genes within
the tissue-specific gene dataset was determined using the Fisher’s Exact Test.

qRT-PCR
Total RNA was isolated and subjected to qRT-PCR analysis as described (Slott et al. 1993).
Expression was normalized to the housekeeping genes Actb and Gapdh. Primer pairs are listed in Table
3.3S.

In situ hybridization
Nonradioactive in situ hybridization was performed (Val et al. 2006) using paraformaldehydefixed, paraffin-embedded adrenal sections (5 µm). To prepare riboprobes, cDNA fragments of Igfbp6,
Foxs1, Spinlw1, and Foxl2 were amplified by RT-PCR (annealing temperature = 52º C) and cloned into
the vector pCRII-TOPO (Invitrogen, Carlsbad, CA) using the manufacturer’s guidelines. RT-PCR primers
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and cDNA fragment sizes are specified in Table 3.S4. Digoxygenin-labeled antisense riboprobes were
synthesized from EcoRV-linearized plasmids using Sp6 RNA polymerase (Heikinheimo et al. 1994).
Bound riboprobe was detected using an alkaline phosphatase conjugated anti-digoxigenin antibody, as
described (Val et al. 2006). Sections were subsequently counterstained with nuclear fast red.

Immunohistochemistry
Mouse tissues were fixed overnight in 4% paraformaldehyde in PBS, embedded in paraffin,
sectioned (5 µm), and subjected to immunoperoxidase staining (Anttonen et al. 2003). Formalin-fixed,
paraffin-embedded, adrenocortical neoplasms from gonadectomized ferrets were obtained from the
archives of a veterinary diagnostic laboratory, as reported previously (Peterson et al. 2003; Peterson et
al. 2004; Wagner et al. 2008); included were cases of adrenocortical carcinoma, adenoma, and nodular
hyperplasia. Criteria for classification of these tumors are listed elsewhere (Peterson et al. 2003). The
primary antibodies were: a) rabbit anti-INSL3 (sc-134587; Santa Cruz Biotechnology, Santa Cruz, CA;
1:200 dilution), b) goat anti-GATA4 (sc-1237, Santa Cruz Biotechnology; 1:200 dilution), and c) goat antiFOXL2 (IMG-3228; Imgenex, San Diego, CA; 1:400 dilution). Secondary antibodies were: a) goat antirabbit biotinylated IgG (NEF-813, NEN Life Science, Boston, MA; 1:2000 dilution) and b) donkey anti-goat
biotinylated IgG (Jackson Immunoresearch, West Grove, PA; 1:1000 dilution). The avidin-biotin
immunoperoxidase system (Vectastain Elite ABC Kit, Vector Laboratories, Inc., Burlingame, CA) and
diaminobenzidine were used to visualize the bound antibody. The analysis included negative control
studies in which the primary antibodies were omitted.

Data Release
The DNA methylation data generated for the study can be found under GEO accession number
GSE45361. DNA methylation and raw sequence data are also publically available at the Center for
Genome Sciences (www.cgs.wustl.edu/~maxim/). The microarray hybridization data has been
deposited under GEO accession number GSE54393.
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FIGURE 3.1

Figure 3.1 Two genes identified as hypomethylated by genome-wide mapping, Igfbp6 and Foxs1,
are upregulated in GDX-induced adrenocortical neoplasms of the mouse. (A) qRT-PCR analysis of
Igfbp6 and Foxs1 in whole adrenal mRNA from non-gonadectomized (nGDX) or gonadectomized (GDX)
female DBA/2J mice (n = 4 per group). (B) qRT-PCR analysis of Igfbp6 and Foxs1 in normal or tumor
tissue isolated by LCM from the adrenal cortex of ovariectomized DBA/2J mice (n = 4 per group). qRT64

PCR results were normalized to expression of Actb (*, P < 0.05); normalization to Gapdh yielded similar
results. Statistical significance was determined using the Student’s t test. (C) In situ hybridization of
adrenal tissue from an ovariectomized DBA/2J mouse using an Igfbp6 antisense riboprobe. (D) H&E
staining of an adjacent tissue section. Igfbp6 mRNA localized to neoplastic cells in the subcapsular
region. (E) In situ hybridization of adrenal tissue from an ovariectomized DBA/2J mouse using a Foxs1
antisense riboprobe. (F) H&E staining of an adjacent tissue section. Foxs1 mRNA localized to neoplastic
tissue in the subcapsular region and to cells in the medulla (m). Bars = 50 µm.
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FIGURE 3.2

Figure 3.2 The Sf1 FAdE is hypomethylated in normal and neoplastic adrenocortical cells. Tissue
from female DBA/2J mice was subjected to DNA methylation analysis using bisulfite-specific PCR. (A)
The graph compares the level of methylation across 7 of 8 CpG dinucleotides in the Sf1 FAdE for various
th

tissues. The 8 CpG (CpG-2) was omitted from the analysis because the data did not pass quality control
measures for pyrosequencing. (B) The inset shows P values for paired t-tests among the different tissue
types. Synthetic DNA is included as a negative control. Note that the FAdE is hypomethylated in the Xzone, normal cells of the zona fasciculata + zona glomerulosa (zF + zG), and post-GDX adrenocortical
tumor tissue.
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FIGURE 3.3

Figure 3.3 Systematic transcriptome analysis shows that genes upregulated in the adrenal glands
of gonadectomized mice are more likely to be highly expressed in ovary or testis than in other
tissues. Probes that were differentially expressed in microarrays of whole adrenal glands from
gonadectomized vs. non-gonadectomized female DBA/2J mice were compared to pooled GEO
microarray data for different mouse tissues using an established rank sum algorithm (Chen et al. 2013).
Probes specific for ovary, testis, adrenal or brain are shown as yellow circles. Probes that were
upregulated in adrenal glands from gonadectomzied mice are shown as red circles (↑ GDX). Probes that
were downregulated in adrenal glands from gonadectomzied mice are shown as blue circles (↓ GDX).
Enrichment analysis demonstrated that genes upregulated in the adrenal glands of gonadectomized mice
were more likely to be highly expressed in ovary (A) or testis (B) than in brain (D). Genes downregulated
in the adrenal glands of gonadectomized mice were more likely to be highly expressed in the normal
adrenal tissue (C) than in brain (E).
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FIGURE 3.4

Figure 3.4 Two genes identified by microarray expression profiling, Spinlw1 and Insl3, are
upregulated in GDX-induced adrenocortical neoplasms of the mouse. (A) qRT-PCR analysis of
Spinlw1 and Insl3 in whole adrenal mRNA from non-gonadectomized (nGDX) or gonadectomized (GDX)
female DBA/2J mice (n = 4 per group). (B) qRT-PCR analysis of Spinlw1 and Insl3 in normal or tumor
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tissue isolated by LCM from the adrenal cortex of ovariectomized DBA/2J mice (n = 4 per group). qRTPCR results were normalized to expression of the housekeeping gene Actb (*, P < 0.05); normalization to
Gapdh yielded similar results. Statistical significance was determined using the Student’s t test. (C) In situ
hybridization of adrenal tissue from an ovariectomized DBA/2J mouse using a Spinlw1 antisense
riboprobe. (D) H&E staining of an adjacent tissue section. Spinlw1 mRNA localized to neoplastic cells in
the subcapsular region. (C) Immunoperoxidase staining of adrenal tissue from an ovariectomized DBA/2J
mouse using anti-INSL3. (D) H&E staining of an adjacent tissue section. INSL3 immunoreactivity was
evident in lipid-laden type B neoplastic cells [see (Bielinska et al. 2006a) for a description of this cell type].
Control experiments demonstrated INSL3 immunoreactivity in Leydig cells of the adult testis (data not
shown). Bars = 50 µm.
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FIGURE 3.5

Figure 3.5 Foxl2 is upregulated in GDX-induced adrenocortical neoplasms of the mouse. (A) qRTPCR analysis of Foxl2 in whole adrenal mRNA from non-gonadectomized (nGDX) or gonadectomized
(GDX) female DBA/2J mice (n = 4 per group). (B) qRT-PCR analysis of Foxl2 in normal or tumor tissue
isolated by LCM from the adrenal cortex of ovariectomized DBA/2J mice (n = 4 per group). qRT-PCR
results were normalized to expression of the housekeeping gene Actb (*, P < 0.05); normalization to
Gapdh yielded similar results. Statistical significance was determined using the Student’s t test. (C) In
situ hybridization of adrenal tissue from an ovariectomized DBA/2J mouse using a Foxl2 antisense
riboprobe. (D) H&E staining of an adjacent tissue section. Bar = 50 µm. (E) Immunoperoxidase staining
of adrenal tissue from an ovariectomized DBA/2J mouse using anti-FOXL2. (F) H&E staining of an
adjacent tissue section. Nuclear FOXL2 immunoreactivity was evident in both small, basophilic type A
neoplastic cells and large, lipid-laden type B neoplastic cells [see (Bielinska et al. 2006a) for a description
of these cell types]. Control stainings demonstrated nuclear FOXL2 immunoreactivity in granulosa cells
of the adult ovary (data not shown). Bar = 50 µm.

70

FIGURE 3.6

Figure 3.6 FOXL2 immunoreactivity in neoplastic adrenocortical cells from a gonadectomized
female ferret with clinical evidence of ectopic sex steroid production. Sections of normal (A,C,E) or
neoplastic (B,D,F) adrenal cortex were subjected to H&E staining (A,B) or to immunoperoxidase staining
with anti-FOXL2 (C,D) or anti-GATA4 (E,F). The neoplastic tissue contained a mixture of small,
basophilic cells and large, polyhedral cells. Nuclear GATA4 immunoreactivity was evident in both the
small and large neoplastic cells, whereas nuclear FOXL2 immunoreactivity was limited to the large
neoplastic cells in this specimen. Bar = 50 µm. Abbreviations: c, capsule; zF, zona fasciculata; zG, zona
glomerulosa; zI, zona intermedia [a zone characteristic of ferrets and other carnivores (Holmes 1961)].

71

SUPPLEMENTARY FIGURES AND TABLES
FIGURE 3.S1

Figure 3.S1 FOXL2 immunoreactivity in an adrenocortical tumor from a gonadectomized male
ferret with clinical signs of ectopic sex steroid production. Nuclear FOXL2 staining is evident a
subset of the neoplastic cells (arrowheads) but not in normal adrenocortical cells (arrow). Bar = 50 µm.
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TABLE 3.S1
https://cgs.wustl.edu/~maxim/Thesis/Chapter3/Table3.S1.xlsx
Table 3.S1 Microarray expression profiling of adrenal glands from gonadectomized (GDX) vs. nongonadectomized (nGDX) female DBA/2J mice. Genes that were significantly upregulated or
downregulated (> 2-fold) are listed in the first tab. Genes that survived the Benjamini-Hochberg
correction are listed in the second tab. See Materials and Methods for details.

TABLE 3.S2
https://cgs.wustl.edu/~maxim/Thesis/Chapter3/Table3.S2.xlsx
Table 3.S2 Genes deemed tissue-specific for adrenal, brain, ovary, and testis based on analysis of
pooled GEO microarray data. See Materials and Methods for details.

TABLE 3.S3

Gene
Actb
Foxl2
Foxs1
Gapdh
Igfbp6
Insl3
Spinlw1

Primer sequence (5' → 3')
F: GCGTGACATCAAAGAGAAGC
R: AGGATTCCATACCCAAGAAGG
F: GCAAGGGAGGCGGGACAACAC
R: GAACGGGAACTTGGCTATGATGT
F: TACCTCGCCCTCACCGTGCC
R: CAAGGCCTGGGTCAGTCCCCA
F: GCTCACTGGCATGGCCTTCCGTG
R: TGGAAGAGTGGGAGTTGCTGTTGA
F: CAGAGACCGGCAGAAGAATC
R: GCTTCCTTGACCATCTGGAG
F: CACGCAGCCTGTGGAGACCC
R: CGCTGGCGCTGAGAAGCCT
F: TGACTTGCTGTTTCCCAGGAG
R: AAGCCATACAGTAGCCGGAG

Table 3.S3 Primers used for qRT-PCR.
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cDNA size
(bp)

Reference

187

NM_007393.2

154

NM_02020.2

167

NM_010226

200

NM_008084.2

289

NM_008344

134

NM_013564.7

191

NM_029325.2

TABLE 3.S4

Gene
Spinlw1
Foxl2
Foxs1
Igfpb6

Primer sequence (5' → 3')

Size (bp)

F: GTGCTATTTGGCCTGCTTGC
R: TAGGACCCCACAACTGGGAA
F: CAAGTACCTGCAATCGGGGT
R: TGCGTCTCAGACACTTCGAC
F: TCACCGTGCCCAGCATTCGG
R: CCCCAAGGGACCTGCCTGACT
F: TGTTGGTTCGTTGCGGGCTCA
R: CCTGCGAGGAACGACCTGCTG

Table 3.S4 Primers used to generate riboprobes for in situ hybridization.
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513
490
513
561

CHAPTER 4: ACTIVE METHYLATION AND DEMETHYLATION IN MOTOR NEURON MATURATION

ABSTRACT
Cytosine methylation (5mC) and hydroxymethylation (5hmC) play important roles in
transcriptional regulation in post-mitotic neurons. Neuronal activity-induced gene activation in the adult
brain is mediated through the Tet oxidation of 5mC to 5hmC, which is replaced with unmodified cytosine
by the base excision repair pathway to complete the demethylation cycle. Little is known about the
dynamics of how 5mC and 5hmC are established in adult neurons partially owing to the difficulty of
studying neuron maturation ex vivo. Here, we leverage a recently developed 5mC genome-wide mapping
technique and a motor neuron puromycin-selectable transgenic embryonic stem cell line to characterize
the DNA methylome of motor neurons (MNs) as they differentiate and mature. We show that motor
neuron differentiation and maturation is characterized by a loss of 5mC at genes critical for neuron
function and by a global gain in 5hmC. These changes in cytosine modification result in attendant gene
activation and show enrichment for known sequence motifs of motor neuron-specific transcription factors.
Furthermore, single, double, and triple knockout experiments show that individual Tet proteins are not
required for MN maturation and that Tet3 is sufficient for proper MN differentiation and maturation, and
that MN can differentiate and form without the presence of any TET enzymes. Our study suggests that
transcription factor-mediated active demethylation of 5mC through the 5hmC intermediate occurs in a
temporal manner and that the TET proteins play redundant and compensatory roles in MN differentiation
and maturation.
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INTRODUCTION
Motor neurons (MNs) connect the central nervous system and skeletal muscle to direct muscle
contractions and movement. They are primarily located in the ventral horn of the spinal cord where axons
extend to muscle cells at neuromuscular junctions. MN diseases, like amyotrophic lateral sclerosis (ALS),
result in axon degeneration and eventual paralysis, organ failure, and death. In normal development, MNs
are completely formed by embryonic day 13 (E13) in the mouse and gestation week 5.5 in humans
(Altman J. 2001). In vivo studies have shown that MN maturation is characterized by changes in
morphology and electrophysiology. As MNs mature, they increase in cell body size, extend peripheral
axons, and form dendrites (Cullheim et al. 1987; Nunez-Abades and Cameron 1995; Burke and Glenn
1996; Altman J. 2001; Carrascal et al. 2005; Li et al. 2005), and are able to fire multiple action potentials
to propagate synaptic signaling (Ziskind-Conhaim 1988; Martin-Caraballo and Greer 1999; Carrascal et
al. 2005). Previously, McCreedy et al. developed a transgenic mouse embryonic stem cell line that allows
for the selection of motor neurons in culture. This in vitro differentiation method, and others, have
demonstrated that normal cell morphology and electrophysiology can be recapitulated in cultured MNs
(Wichterle et al. 2002; Miles et al. 2004; Wichterle and Peljto 2008; Takazawa et al. 2012).
The covalent modification of cytosine in the genome is associated with gene silencing and is vital
for normal development (Reik 2007) and for maintaining cellular identity (Dhawan et al. 2011b). The
methylation of cytosine (5mC) has been extensively studied in neurons of the brain (Iwamoto et al. 2011;
Lister et al. 2013; Kozlenkov et al. 2014) and has been shown to influence synaptic formation (Levenson
et al. 2006), learning and memory (Day and Sweatt 2010; Miller et al. 2010; Zovkic et al. 2013), emotional
behavior (LaPlant et al. 2010), adult neurogenesis (Ma et al. 2009), and age-related cognitive decline
(Oliveira et al. 2012). Although originally thought to be a permanent covalent modification in neurons,
5mC levels change in response to external stimuli (Guo et al. 2011a). Recent studies have identified
CpGs that are modified in postnatal neural tissues upon neuronal activity induced by voluntary exercise
(Guo et al. 2011a), social stress conditions (McGowan et al. 2009; Elliott et al. 2010), and
electroconvulsive stimulation (Guo et al. 2011a). The necessity for functional DNA methyltransferase and
CpG-binding proteins in ensuring long-term neural plasticity and cognition further highlights the
importance of 5mC in normal neuron function (Moretti et al. 2006; Feng et al. 2010). Although the
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importance of 5mC in neurons of the brain is well established, little is know about the role 5mC plays in
motor neuron maturation.
The discovery of the hydroxymethylation of cytosine (5hmC) has introduced an additional role of
cytosine modification in the brain (Penn et al. 1972; Tahiliani et al. 2009). 5hmC occurs primarily at gene
bodies and is associated with gene activation (Branco et al. 2012). The presence of 5hmC varies across
tissue types but is highest in the hypothalamus and cerebral cortex (Globisch et al. 2010) suggesting it
plays an important role in neuron function. 5hmC is an intermediate for the demethylation of 5mC
(Tahiliani et al. 2009; Guo et al. 2011b) and knockout experiments have shown that the oxidation of 5mC
to 5hmC by TET1 is necessary for neuronal activity-induced active DNA demethylation in the adult mouse
brain (Guo et al. 2011b). Although significant progress has been made in understanding the role of 5mC
and 5hmC in neurons of the developing brain, it is unknown whether 5hmC is present in motor neurons
and whether the Tet demethylating machinery is necessary for normal motor neuron function.
In this study, we used Laser Capture Microdissection-Reduced Representation Bisulfite
Sequencing (LCM-RRBS) to profile the genome-wide 5mC and used immunocytochemistry to profile
global 5hmC of a pure population of differentiating and maturing MNs in vitro. We show that post-mitotic
MNs undergo significant methylome remodeling upon differentiation and functional and morphological
maturation. The observed methylation changes are associated with transcriptional changes of genes
important for motor neuron function. Furthermore, we show that the presence of 5hmC in MNs occurs
post-differentiation upon cellular maturation and that the Tet demethylation machinery is necessary for
proper motor neuron differentiation and maturation. We provide the first global view of the changing DNA
methylation landscape at base pair resolution in developing motor neurons.

RESULTS
In vitro selected motor neurons model morphological and electrophysiological motor neuron
maturation in culture
Current in vitro studies of MN maturation are limited by the presence of proliferating glial cells that
prevent the isolation of individual neurons. Previously, McCreedy et al. characterized a transgenic Hb9driving puromycin (Hb9-puro) transgenic embryonic stem cell line that, upon retinoic acid and sonic
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hedgehog induction, differentiates into physiologically normal MNs. Induced neural progenitor cells
(NPCs) express the spinal motor neuron-specific transcription factor, Hb9, and therefore also express
Puromycin N-acetyltransferase, which can be used to select for MNs (Figure 4.1). To better understand
the utility of the Hb9-puro line as a model for studying MN maturation, we characterized the morphology
and electrophysiology of maturing MNs at 24 hours (D0), two days (D2), and four days (D4) after
differentiation and selection. We first assessed the formation of neurites, branch points, neuronal
networks, cell area, and neurite length as a function of time. β-tubulin class III staining, imaging, and
quantification showed a statistically significant increase (ANOVA, P<0.05) in neurite number, neurite
length, neurite branch points, and cell body area from D0 to D4 (Figure 4.2 and 4.3). Furthermore, as
MNs developed neurites, they formed an increasing number of contacts with neighboring cells to
establish closed networks as represented by a decrease in independent networks across time (Figure
4.3). Most neurite growth and branching occurred from D0 to D2 after which neurite growth slowed
(Figure 4.2 and 4.3). We conclude that cultured MNs are morphologically mature at four days after
differentiation.
We next investigated the electrophysiological properties of D0, D2, and D4 MNs. Previous work
by McCreedy et al. showed that D4 MNs have the ability to fire multiple action potentials during periods of
prolonged depolarization and exhibit adaptation in both spike frequency and amplitude. To evaluate the
functional properties of selected MNs over time, we performed whole-cell current-clamp recordings
between 0 and 6 days after differentiation (puromycin selection; Figure 4.4). To test for expression of
functional neurotransmitter receptors, we exposed cells to selective agonists for AMPA/kainate, NMDA,
glycine, and GABA receptors and recorded the resulting inward current. Figure 4.4 (top panel) shows that
-4

the amplitude of agonist-evoked total whole-cell current density increases with time (Pearson, P<10 )
after puromycin selection, suggesting the number of channels expressed on the surface of each cell
increases over time. Interestingly, currents evoked by AMPA/kainite, NMDA, and glycine agonists showed
the greatest increase from D2 to D4 while the largest increase in current density evoked by the GABA
agonists was observed between D0 and D2, suggesting GABA receptor expression occurs earlier than
AMPA/kainite, NMDA, and glycine receptors. Furthermore, whole-cell capacitance, which is proportional
to surface area, significantly increased from 22.6 ± 1.5 pF (n=11) at D0 to 61.2 ± 4.0 pF (n=16) at D6
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(ANOVA, P<10 ) while input resistance decreased significantly between D0 and D2 but not between D2
-4

and D4 or D6 (ANOVA, P<10 ), which confirms our morphology experiments that a significant increase in
cell size occurs between D0 and D4 (Figure 4.4, bottom panel). Our results and those from McCreedy et
al. together demonstrate that selected MNs mature into functional neurons by four days after puromycin
selection.

Maturing motor neurons show active gains and losses in DNA methylation at genes implicated in
neurogenesis
Little is known about the role DNA methylation plays in MN maturation. To determine whether
DNA methylation changes occur in maturing MNs, we applied LCM-RRBS (Schillebeeckx et al. 2013) to
three biological replicates of D0, D2, and D4 MNs. Using LCM-RRBS, we were able to interrogate the
DNA methylation status of 1,074,439 CpGs at all three time points. Although >99% of CpGs did not show
a significant change in DNA methylation from D0 to D4, 2,894 CpGs and 1,147 CpGs showed a
statistically significant loss and gain of at least 25 percent methylation, respectively (Figure 4.5, left panel;
Table 4.S1). Although LCM-RRBS enriches for CpGs in promoter regions (Figure 4.S1; top left panel), we
observed that most CpG changes occurred >10 kilobases from the nearest gene (Figure 4.S1; bottom
panel). We, therefore, assessed whether there was an enrichment at introns, exons, promoters, or
intergenic regions. We see a significant depletion of differentially methylated CpGs in promoters (p-16

value<10 ; OR<0.32) and a significant enrichment for differentially methylated CpGs at introns (p-9

-9

value<10 ; OR>1.49) and intergenic regions (p-value<10 ; OR>1.46) (Figure 4.S1). Furthermore,
hypomethylated CpGs were highly enriched for CpGs distal to the nearest gene (Welch’s t test; p-5

value<10 ) while hypermethylated CpGs had a slight enrichment for distal CpGs (Welch’s t test; pvalue<0.039) with a mean distance of 17,709 bp and 14,264 bp, respectively, to the nearest transcription
start site (TSS)(Figure 4.S1). Taken together, we conclude that significant changes in CpG methylation
occur at putative regulatory regions distal to TSSs.
To determine whether the differentially methylated CpGs regulate genes important for motor
neuron function, we identified the nearest gene to each differentially methylated CpG and performed
Gene Ontology enrichment analysis. Hypomethylated CpGs were associated with genes enriched for
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neuronaI function, including neuron projection guidance, axon guidance, and neuron differentiation while
hypermethylated CpGs were associated with genes enriched for cell differentiation, including embryonic
-6

morphogenesis, regulation of cell development, and multicellular organismal development (q-value<10 ;
FDR-adjusted; Table 4.1). Interestingly, changes in DNA methylation occurred at various stages in MN
maturation. Roughly 65% of hypomethylated CpGs lost more methylation between D0 and D2 than
between D2 and D4 while roughly 65% of hypermethylated CpGs gained more methylation between D2
and D4 than between D0 and D2 (Figure 4.5, right panel; Table 4.S1), suggesting gene activation occurs
earlier than gene silencing. We conclude that hypomethylated CpGs are associated with genes important
for motor neuron maturation and that the loss of CpG methylation occurs within two days after
differentiation.
To assess whether the observed loss of methylation is specific to MNs, we determined the
methylation states of hypomethylated CpGs for astrocytes, a glial cell type. Astrocytes and MNs share a
common progenitor and, therefore, have a close epigenetic origin in which they stem from one DNA
methylation profile. We find that CpGs hypomethylated in MNs are enriched for CpGs that are highly
-16

methylated in astrocytes (Figure 4.6; Fisher’s Exact Test, p-value<10 ). Indeed, 82% of hypomethylated
CpGs are highly methylated in astrocytes with a percent methylation of 75% or greater, suggesting the
observed loss of DNA methylation is specific to MNs. Together, we conclude that maturing MNs show
significant gains and losses of DNA methylation at CpGs associated with genes implicated in neuronal
functions and cellular differentiation and that the loss of DNA methylation is specific to motor neurons.

Motor neurons show a significant increase in expression of genes associated with active
demethylation
DNA methylation at gene promoters acts to silence genes by recruiting chromatin modifying
proteins or by preventing transcription factor binding and is therefore negatively correlated with gene
expression (Watt and Molloy 1988; Robertson 2005). We hypothesized that the observed gains and
losses of DNA methylation would be associated with gene silencing and gene activation, respectively. To
test this hypothesis, we performed gene expression profiling of neural progenitor cells (NPC) and
selected MNs at D0, D2, and D4 (Table 4.S2). We found 142 and 50 genes that showed a statistically
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significant (q-value<0.05; FDR-adjusted) increase or decrease in expression between D0 and D4 MNs,
respectively (Figure 4.7; left panel). Upregulated genes were enriched (q-value<0.05; FDR-adjusted) for
neuronal function, including cell signaling, synaptic transmission, and neuromuscular process while
downregulated genes were enriched (q-value<0.05; FDR-adjusted) for various biological processes
including apoptosis and biosynthesis (Table 4.2). Furthermore, upregulated genes were enriched (qvalue<0.05; FDR-adjusted) for ion channels, transporters, and neurotransmitter receptors (Table 4.3).
Unsupervised hierarchical clustering of differentially expressed genes suggests that the majority of
expression changes occur with two days of MN differentiation with fewer changes occurring between D2
and D4 than between D0 and D2 (Figure 4.7; right panel). Therefore, within two days of differentiation,
motor neurons undergo significant gene activation and gene silencing as they mature into functioning
neurons.
To assess whether differentially methylated CpGs were associated with an expression change,
we determined the expression level of genes associated with hypomethylated and hypermethylated CpGs
across NPCs, D0 MNs, D2 MNs, and D4 MNs. We found that 82 and 21 genes upregulated and
downregulated in D4 MNs, respectively, were associated with differentially methylated CpGs (Fisher’s
-16

Exact; p-value<10 ; Figure 4.8). Of the 82 upregulated genes, 64 were associated with a distal CpG that
significantly lost DNA methylation between D0 and D4 MNs (Figure 4.S2) while 13 downregulated genes
were associated with a distal CpG that gained DNA methylation (data not shown). Taken together, we
find that as they mature, MNs undergo significant expression changes that correlate with concomitant
changes in DNA methylation.

Motif scanning identifies factors associated with active gains and losses of DNA methylation in
maturing motor neurons
DNA methylation can prevent the binding of transcription factors (TFs) to DNA by directly
occluding binding sites or by recruiting methyl-binding proteins (Watt and Molloy 1988). We hypothesize
that differentially methylated CpGs may lie within gene regulatory regions important for MN maturation
and differentiation and that the methylation status of these CpGs may regulate TF binding and gene
regulation. To elucidate whether differentially methylated regions are associated with TF binding, we
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evaluated 100 bp regions flanking hypomethylated and hypermethylated CpGs for the enrichment of
known TFs using the Hypergeometric Optimization of Motif EnRichment (HOMER) suite of tools (Heinz et
al. 2010). We find 96 and 9 predicted motifs corresponding to known cognate TFs that were enriched in
hypomethylated and hypermethylated regions, respectively (q-value<0.01; FDR-adjusted). To elucidate
which TFs may contribute to MN function, we performed gene ontology enrichment analysis on the TFs
that were found predicted by HOMER to bind hypomethylated and hypermethylated regions. We found
that 14 TFs associated with hypomethylation are enriched for neuronal function (Table 4.4). Indeed, the
TFs Isl1, Phox2a, Lhx3, Tbx20 are known to play critical roles in spinal and cranial MN differentiation
(Mazzoni et al. 2013). Of these 14 TFs, 10 show a statistically significant (p-value<0.05; FDR-adjusted)
expression difference between NPCs and D0 MNs as assessed by microarray analysis (Figure 4.S3). Isl1
and Lhx3 had the highest increase and decrease in expression, respectively, from NPCs to D0 MNs. We
also find that hypermethylated regions were enriched for Oct4, a pluripotency factor, and Olig2, a neurooligodendrocyte cell-type specification factor. These findings suggest Isl1 may direct demethylation of
CpGs during motor neuron maturation while Lhx3 may play a role in maintaining CpGs in a methylated
state prior to differentiation.

Maturing motor neurons gain 5-hydroxymethylation over time
We previously demonstrated that MNs lose DNA methylation at 2,894 CpGs as they mature.
Because MNs no longer undergo cell division after selection (D0), the loss of DNA methylation we
observe between D0 and D4 is indicative of an active demethylation pathway, independent of cell
division. Several mechanisms for active demethylation have been proposed (Branco et al. 2012; Kohli
and Zhang 2013) but all require the active oxidation of 5-methylcytosine (5mC) to a 5hydroxymethylcytosine (5hmC) intermediate by the Ten-eleven translocation (Tet) family of proteins. We
hypothesized that the loss of 5mC in maturing MNs occurs with a concomitant gain of 5hmC. To test this
hypothesis, we performed immunocytochemistry on fixed D0, D2, and D4 MNs with an antibody directed
at 5hmC. Immunocytochemistry showed very little positive staining for 5hmC at D0 and strong 5hmC
signal at D2 and D4 (Figure 4.9). We conclude that MNs gain significant 5hmC as they mature to
functional neurons.
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TET proteins are necessary for proper motor neuron differentiation and maturation
Our microarray expression analysis shows a statistically significant increase in Tet2 and Tet3
expression in D0 MNs as compared to NPCs (Student’s t test; p-value<0.05; Figure 4.S4). Furthermore,
qRT-PCR analysis of ES cells shows an increase in Tet3 expression as they differentiate into NPCs
(Figure 4.S5). The observed changes in gene expression of the TET proteins and the observed increase
in 5hmC in maturing MNs (Figure 4.9) prompted us to hypothesize that the Tet family plays a role in MN
differentiation and maturation. To determine whether the Tet family members are necessary for MN celltype specification and maturation, we created Tet1, Tet2, and Tet3 single knockout, Tet1/Tet2 double
knockout (DKO), and Tet1/Tet2/Tet3 triple knockout (TKO) Hb9-puro ES cells using the CRISPR/Cas9
genome engineering system (Figure 4.S6). Similar to wildtype cells, all knockout cell lines formed EBs
and NPCs when ES cells were induced to differentiate with retinoic acid and sonic hedgehog agonist
(data not shown). Tet1, Tet2, and Tet3 single knockout NPCs developed into normal MNs and showed
normal gains of 5hmC by D4 (Figure 4.10). Interestingly, single knockout MNs, unlike wildtype MNs
showed the presence of 5hmC at D0 as well (Figure 4.10). Immunocytochemistry staining showed a
dramatic reduction in MN differentiation in DKO cells compared to wildtype cells but showed normal gains
of 5hmC in the viable MNs that formed (Figure 4.11). TKO cells showed an almost complete inability to
differentiate into MNs; curiously, the few MNs that did differentiate and mature showed strong 5hmC
staining (Figure 4.11).
Differentiation experiments with single knockout ES cells suggest all three TET proteins can
convert 5mC to 5hmC and play redundant roles in MN maturation. The presence of viable Tet1/Tet2 DKO
MNs suggests Tet3 is sufficient for MN differentiation and can compensate for the lack of TET1 and TET2
protein, which is consistent with experiments showing that Tet1/Tet2 DKO ES cells form viable and
grossly normal mice (Dawlaty et al. 2013). The significant reduction in differentiation potential of
Tet1/Tet2/Tet3 knockout NPCs suggests the TET proteins are necessary for normal differentiation. A few
TKO MNs, however, did successfully differentiate and mature. These TKO MNs seem morphologically
normal and show strong 5hmC staining. The presence of 5hmC in MNs that completely lack any Tet
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machinery suggests the TET proteins are not necessary for MN maturation and that an as of unknown
protein can mediate the hydroxymethylation of cytosine.

DISCUSSION
In this study, we show that MNs undergo significant epigenetic and gene expression changes as
they mature. We leverage an Hb9-puro cell line to culture pure populations of spinal MNs and leverage
the LCM-RRBS method to interrogate genome-wide DNA methylation of the limited genomic material. We
find that MN maturation is characterized by a loss of cytosine methylation (5mC) and a gain of cytosine
hydroxymethylation (5hmC) although gains of cytosine methylation are also observed. We find that the
majority of methylation loss results in an increase in expression of the nearest gene. Interestingly,
methylation and expression changes did not always co-occur. Indeed, we find CpGs that require four
days to become fully demethylated but the CpG’s nearest gene is significantly activated within one or two
days after differentiation. For example, methylation loss of a CpG near the App gene occurs 2-4 days
after differentiation yet App expression significantly increases within one day of differentiation (Figure
4.S7). In most cases, however, CpG methylation correlates well with expression change (Table 4.S3). For
example, CpGs associated with Ret, on the other hand, show a loss of DNA methylation at Day 2 with a
concomitant increase in Ret expression (Figure 4.S7). The difference in transcriptional timing and loss of
DNA methylation suggests other epigenetics factors could be regulating the activation of MN-specific
transcriptional profiles.
Combinatorial TF expression defines a cell’s identify. Isl1, Lhx3, and Hb9 expression characterize
spinal MNs while Isl1, Phox2a, and Tbx20 expression characterize branchiomotor and visceromotor
(cranial) neurons (Mazzoni et al. 2013). Interestingly, motif scanning of hypomethylated regions revealed
the enrichment of putative binding motifs for both spinal (Isl1 and Lhx3) and cranial (Phox2a and Tbx20)
MN TFs (Table 4.4). Mazzoni et al. showed that Isl1 directly interacts with Lhx3 and Phox2a in a cell-type
dependent manner, which may explain the enrichment for Phox2a binding motifs. We predict that known
Isl1-Phox2a binding sites of cranial MNs show an enrichment for hypomethylated regions relative to
NPCs in cranial MNs. Furthermore, the hypomethylated regions we have identified may also be important
for proper differentiation and maturation of cranial motor neurons.
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We also evaluated the presence of genome-wide cytosine hydroxymethylation (5hmC) in
maturing MN cultures by immunocytochemistry. We find that MNs have very little 5hmC 24 hours after
differentiation (Day 0) but gain genome-wide 5hmC within two days of maturation (Figure 4.9). Wholegenome 5hmC mapping techniques will elucidate where in the genome the 5hmC increases as MNs
mature and whether the gain of 5hmC correlates with gene expression as is suggested by recent studies
(Jin et al. 2011; Tan et al. 2013). Hb9 expression peaks during NPC differentiation 4 days after EBs are
induced with retinoic acid/Shh agonist and marks post-mitotic cells (Li et al. 2008b). Hb9-expressing
NPCs, therefore, do not undergo any cell division during puromycin selection or maturation. Surprisingly,
despite seeing no 5hmC in NPCs (Tan et al. 2013) or D0 MNs (Figure 4.9), we observe active
demethylation at over 23,000 CpGs between NPCs and D0 MNs (data not shown), suggesting the active
loss of methylation from NPCs to D0 MNs does not occur through the Tet pathway. Because NPCs
consist of heterogeneous cells expressing different neuronal markers, DNA methylation analysis of Hb9+
FACS-enriched NPCs along with genome mapping of 5hmC in Hb9+ NPCs and D0 MNs would validate
whether the aforementioned hypomethylated events are due to active demethylation mediated by the Tet
machinery or due to other active demethylating pathways.
Finally, we show that Tet1, Tet2, and Tet3 play redundant, compensatory roles in MN
differentiation and maturation, which is consistent with single knockout mice studies (Dawlaty et al. 2011).
Expression analysis shows an increase in Tet2 and Tet3 expression between NPCs and D0 MNs (Figure
4.S4) as well as high expression of Tet3 in whole mouse spinal cords (Figure 4.S5) suggesting Tet2 and
Tet3 are important for MN function. We find that single knockout ES cells can be induced to differentiate
into normal MNs that show normal 5hmC gains demonstrating that no single Tet is required for MN
differentiation and maturation. Furthermore, we find that Tet1/Tet2 double knockout cells also differentiate
into MNs, albeit less efficiently than wildtype cells, and show normal 5hmC gains, demonstrating that Tet3
is sufficient for MN differentiation and maturation. Tet1/Tet2/Tet3 triple knockout cells show a striking
reduction in ability to differentiate but are able to form mature MNs, demonstrating that the presence of
Tet is necessary for normal differentiation of MNs. Significant validation of the lack of Tet protein as well
as quantification of morphology, differentiation, and 5hmC levels is necessary to support the experiments
herein. Tet1/Tet3 and Tet2/Tet3 double knockout studies along with DNA methylation analysis of all
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knockouts will further elucidate the overlapping role and genome specificity of each of the Tet proteins in
MN maturation.

Model for active DNA methylation and gene activation in motor neuron differentiation
Our findings support a model where neuron-specific transcription factors recruit the Tet
machinery to actively demethylate enhancer regions and activate genes critical to normal MN function
(Figure 4.12). In this model, Isl1 binding sites at distal regulatory regions are methylated in NPCs (1).
Upon NPC differentiation into MNs, Isl1 expression increases, binds at these regions, and recruits the Tet
demethylases and other factors to remove DNA methylation (2). Upon demethylation by Tet, MN-specific
target genes (e.g. Ret) are activated (3). Co-immunoprecipitation experiments of Isl1 and Tet will directly
test whether they interact and form a DNA-binding complex.
In conclusion, we present the first known evidence of active demethylation in maturing spinal
MNs and report the derivation of Tet1, Tet2, and Tet2 single, Tet1/Tet2 double, and Tet1/Tet2/Tet3 triple
ES knockouts that can be differentiated and selected to create pure MN cultures. We show that all
knockouts are able to form morphologically mature MNs and that the double and triple knockout lines
have a significantly reduced ability to differentiate into MNs. The DNA methylation (5mC and 5hmC) and
gene expression data from this study will inform future experiments to help elucidate the role of cytosine
methylation in MN differentiation, maturation, and viability. Furthermore, the knockout embryonic stem cell
lines derived in this study will facilitate research on dissecting the role of Tet family members in the
differentiation of many other cell types as well as their roles in MN maturation.
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MATERIALS AND METHODS

Embryonic stem cell cultures
Mouse ES cells were cultured on gelatin-coated T75 flasks in complete media consisting of
Dulbecco’s Modified Eagle Medium (DMEM; Life Technologies, Carlsbad, CA) containing 10% newborn
calf serum (Life Technologies), 10% fetal bovine serum (Life Technologies), and 30 µM of each of the
following nucleosides (Sigma): adenosine, cytosine, guanosine, and uridine. For routine culture, ES cells
were passaged every two days. Briefly, ES cells were washed with DMEM containing 25 mM HEPES
(Life Technologies) and dissociated with 0.25% trypsin-EDTA (Life Technologies) for 5 min. Trypsin was
quenched with fresh complete media and cells were transferred to a new gelatin-coated flask at a 1:5
ratio in fresh complete media containing 1000 U/mL leukemia inhibitory factor (LIF; Millipore, Bellerica,
MA) and 100 µM β-mercaptoethanol (BME; Life Technologies). All cells were cultured at 37°C in the
presence of 5% CO2.

Derivation of Tet1, Tet2, Tet3 knockout Hb9-puro embryonic stem cells
Plasmids containing the Cas9 open reading frame or a guide RNA (gRNA) targeting Tet1, Tet2,
or Tet3 were obtained from the Genome Editing Core at Washington University in St. Louis. Hb9-puro
mouse ES cells were transfected with 0.5 µg of pPB_donor plasmid (which contains a neomycin and
dsRed construct), 1 µg Cas9 plasmid, and 1 µg of gRNA plasmid directed at Tet1, Tet2, and/or Tet3
depending on the intended line using lipofectamine 2000 (Life Technologies) one day after passaging to a
6-well gelatinized plate. One day after transfection, cells were trypsinized and 10% of cells transferred to
a 10 cm gelatinized dish. After incubating for one day, the neomycin analog, G-418, was added at a
concentration of 1-0.5 mg/ml. Two days later, media was replaced with fresh complete media containing
0.5 mg/ml and cultures left to expand for an additional 6 days. Following a media change, individual
colonies were expanded in individual wells of a gelatinized, 96-well, flat-bottom plate and screening by
PCR and Illumina sequencing for insertions or deletions in the target position. Putative knockout lines
were expanded and validated using Sanger sequencing.
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Motor neuron differentiation
Transgenic ES cells were differentiated into MNs using a 2-/4+ RA and smoothened agonist (SAG,
6

Millipore) induction protocol as previously described (McCreedy et al. 2012). Approximately 1 x 10 ES
cells were cultured in suspension on 150 mm petri dishes in modified DFK5 media consisting of
DMEM/F12 base media (Life Technologies) containing 5% knockout serum replacement (Life
Technologies), 1x insulin transferrin selenium (ITS; Life Technologies), 50 µM nonessential amino acids
(Life Technologies), 100 µM β-mercaptoethanol, 5 µM thymidine, and 15 µM of the following nucleosides:
adenosine, cytosine, guanosine, and uridine. During this process, ES cells aggregate into multi-cellular
EBs. After the first two days (2-), the EBs were moved to a 15 mL conical and allowed to settle for 5 min.
The media was aspirated and replaced with 10 mL fresh DFK5 containing 2 µM RA and 600 nM
Smoothen agonist (SAG). EBs were then cultured for an additional 4 days (4+) with media replaced every
2 days.

Motor neuron maturation
After 2-/4+ RA and SAG induction, cell were dissociated in 0.25% Trypsin-EDTA for 15 minutes
and quenched with complete media. Dissociated cells were counted and centrifuged at 240 x g for 5
minutes. Cells were resuspended in DFK5 media containing 5 ng/mL glial-derived neurotrophic factor
(GDNF; Peprotech, Rocky Hill, NJ), 5 ng/mL brain derived neurotrophic factor (BDNF; Peprotech, Rocky
Hill, NJ), 5 ng/mL neurotrophin-3 (NT-3; Peprotech, Rocky Hill, NJ), 4 µg/mL puromycin in water (Sigma)
4

2

and plated at ~6 x 10 cells/cm in individual wells of a poly-ornithine-coated (Sigma) 6-well plate for 24
hours. In parallel, for control cultures not receiving puromycin, cells were resuspended in DFK5 media
4

2

with the growth factor cocktail and plated at ~6 x 10 cells/cm in individual wells of a poly-ornithine-coated
coated 6-well plate for 24 hours. Following selection, cells were fixed for immunofluorescence or media
was replaced with modified DFKNB media consisting of DFK5 and Neurobasal (NB) media (Life
Technologies) mixed at a 1:1 ratio and supplemented with 1x B27, 5 ng/mL GDNF, 5 ng/mL BDNF, and 5
ng/mL NT-3. Cells were cultured in DFKNB media for up to 4 additional days.
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Immunohistochemistry
Cells were fixed in 4% (w/v) paraformaldehyde (Sigma) in phosphate buffered saline (PBS) for 15
minutes at room temperature. Fixed cultures were washed once with PBS and permeabilized with 0.2%
triton-X in PBS for 10 minutes. Cultures were then blocked for 1 hour at room temperature with 5%
normal goat serum (NGS; Sigma) in PBS. Primary antibodies were added to blocked cultures overnight at
4°C at the following dilutions in 2% NGS in PBS: class III β-tubulin (Tuj1, 1:5000, Covance) or 5hydroxymethylation (5hmC, 1:250, Active Motif). Primary antibodies were labeled with the appropriate
AlexaFluor conjugated goat antibodies (Life Technologies) at a 1:1000 dilution in PBS for 1 hours. All
wells were counterstained with DAPI (1:10000; Sigma) to label cell nuclei. Following
immunofluorescence, phase contrast and fluorescent images were captured.

Quantification of motor neuron neurite formation
Five biological replicates of D0, D2, and D4 wildtype MNs were fixed and stained with class III βtubulin as described above (see “Immunohistochemistry). For each time point, 60 images with a ~1/3
overlap at 10x magnification were taken and combined into one image using the photomerge tool in
Adobe Photoshop. Each sample image was then cropped to form images of equal size. Cropped images
were uploaded to the WimNuerite (Wimasis) software for neurite morphology quantification. Student’s t
test was applied to determine statistical significance.

Electrophysiology
D0, D2, D4, and D6 MN cultures were bath perfused with Tyrode’s solution (in mM): 150 NaCl, 4
KCl, 2 MgCl2, 2 CaCl2, 10 glucose, 10 HEPES, pH adjusted to 7.4 with NaOH. Whole-cell electrodes
pulled from borosilicate glass capillaries had an open tip resistance of 2 to 5 MOhm when filled with one
of the following internal solutions (in mM): (1) 140 K-glucuronate, 10 NaCl, 5 MgCl2, 0.2 EGTA, 5 Na-ATP,
1 Na-GTP, 10 HEPES, pH adjusted to 7.4 with KOH; or (2) 140 Cs-glucuronate, 5 CsCl, 5 MgCl2, 10
EGTA, 5 Na-ATP, 1 Na-GTP, 10 HEPES, pH adjusted to 7.4 with CsOH. Current and voltage were
recorded with an Axopatch 200A amplifier, filtered at 1 kHz, digitized at 10 kHz and analyzed off-line with
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Clampfit software (pClamp 9.2). Ligand-gated channel agonists were dissolved in 160 NaCl, 10 HEPES,
2 CaCl2 and applied by local perfusion (Kim et al. 2009).

DNA extraction
Selected cultures contain viable MNs as well as dead cells adhering to the well which can
confound DNA methylation analysis. To degrade non-MN DNA, cells were treated with cell-impermeable
DNase as follows: cells were washed three times with PBS to remove dead cells, 160 µl of DNase
(10mg/ml; Sigma) in 1 ml of DFK5 and 10mM MgCl2 were added to each well and incubated for 2 hours
at 37°C, then stained with DAPI or Hoechst to verify complete degradation of non-MN DNA. Cells were
then washed three times with PBS and scraped off with a rubber scraper and transferred to a 1.5 ml
Eppendorf tube. Collected cells were spun at 16000 rpm for 10 minutes and the supernatant removed
with a pipet. DNA samples were purified using NucleoSpin Tissue XS columns (Clontech) following the
protocol for cultured cells and eluted in 20 µl of nuclease-free water. Genomic DNA was quantified using
the Quant-it dsDNA High Sensitivity kit (Invitrogen) and the Qubit fluorometer (Invitrogen).

LCM-RRBS
LCM-RRBS was performed on three biological replicates of D0, D2, and D4 MNs as described
previously (Schillebeeckx et al. 2013). Briefly, 10 ng of DNA from each of the nine samples was digested
with MspI (NEB), end-repaired, and ligated with pre-annealed methylated paired-end Illumina adapters.
Adapter-ligated fragments were purified using MinElute columns (Qiagen) and bisulfite treated using the
EZ DNA Methylation Gold Kit (Zymo). Each sample was PCR amplified in triplicate using sample-specific
indexed primers using Platinum Taq Polymerase (Invitrogen) and 10 melting-annealing-extension cycles.
All PCR products and replicates were pooled and analyzed by electrophoresis on a 3% 1X Tris-acetateEDTA (TAE) NuSieve agarose gel (Lonza). Fragments between 150 bp and 350 bp were gel extracted
and purified using MinElute columns (Qiagen). To minimize PCR bias, the final PCR library was amplified
in quadruplicate using 11 PCR cycles. The four replicates are pooled and gel extracted to remove
remaining adapter dimers and primers, then purified, and sequenced on Illumina HiSeq 2000 machines.
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Sequence alignment and methylation calling
All analysis was performed using the July 2007 (NCBI37/mm9) build of the mouse genome. On
average 25 million single-end 42-bp raw high quality reads per sample were aligned to the reduced
reference using RRBSMAP (Xi et al. 2012) filtering against reads that contain adapter sequence. Reads
that showed less than 90% bisulfite conversion (~1 unconverted non-CpG cytosine per read) were filtered
to remove those that resulted from incomplete bisulfite converted molecules. Aligned reads with a
mapping quality of zero were also discarded. The resulting high quality uniquely mapped reads were used
for methylation calling. We identified the genomic coordinates of all CpGs in the reference sequence and
assessed percent DNA methylation by calculating the fraction of reads that had an unconverted cytosine
at the CpG position relative to the total reads. We required that each read have either a “TG” or “CG”
dinucleotide at the expected CpG coordinate to be considered for analysis. Differentially methylated
CpGs were determined using a Fisher’s Exact Test comparing the ratio of methylated versus
unmethylated read for each sample. CpGs were considered hypomethylated or hypermethylated if they
showed a statistically significant decrease or increase of at least 25% between D0 and D4 MNs,
respectively.

Microarray expression profiling
RNA was extracted from 2-/4+ RA and SAG induced embryonic stem cells (neural progenitor
cells), D0 MNs, D2 MNs, and D4 MNs using the QIAGEN RNeasy kit. Briefly, cells were resuspended in
lysis buffer RLT (cat no. 79216, QIAGEN) and β-mercaptoethanol, and then disrupted and lysed using a
QIAshredder column (cat no. 79656, QIAGEN). RNA was extracted using a QIAGEN RNeasy Mini kit (cat
no. 74104, QIAGEN) with on-column DNase treatment (cat no. 79254, QIAGEN). Approximately 2 mg of
total RNA per sample was used to prepare cDNA using SuperScript® III, First-strand Synthesis system
(cat no. 18080-051, Invitrogen). Array hybridization was performed by the GTAC Microarray Core facility
at Washington University. Briefly, 50ng of total RNA was used to generate biotinylated cDNA, according
to the standard NuGen WT-Ovation Pico RNA Amplification kit. Following fragmentation with NuGen
Encore Biotin Module, 2.5 ug of cDNA were hybridized onto Mouse Gene 1.0 ST Arrays (Affymetrix) in
the GeneChip Hybridization Oven 640 for 18 hr at 45°C. GeneChips were then washed and stained in the
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Affymetrix Fluidics Station 450 and were scanned using the Affymetrix GeneChip 7G 3000 Scanner. The
scanned raw .CEL files were analyzed to export signal intensity values, using Affymetrix Expression
Console software with Affymetrix default RMA Gene analysis settings. Probe summarization (Robust
Multichip Analysis, RMA), quality control analysis, and probe annotation were performed according to
recommended guidelines (Expression Console Software, Affymetrix). We determined statistical
significance using the Student’s t test and corrected for multiple hypothesis testing using the Benjamini &
Hochberg’s method, leaving a total of 252 probes (q-value < 0.05). Statistically significant upregulated
and downregulated probes correspond to 142 and 50 genes, respectively (Table 4.S2).

Motif scanning analysis
Differentially methylated regions were defined as 200 bp genomic windows flanking a
hypomethylated or hypermethylated CpG. If the CpGs were in a cluster separated by less than
200 bp, then the window was defined to be 100 bp upstream of the first CpG and 100 bp downstream of
the second CpG. Motif scanning was performed on hypomethylated and hypermethylated regions
independently by using the Hypergeometric Optimization of Motif EnRichment (HOMER) suite of tools
HOMER to identify enrichment of known TFs (Heinz et al. 2010). Only motifs with q-values < 0.01
(Benjamini-Hochberg corrected) were considered enriched. We found 92 and 9 sequence motifs enriched
in hypomethylated and hypermethylated regions, respectively, which were used for gene ontology (GO)
enrichment analysis using HOMER tools. GO terms associated with biological processes were Bonferonni
corrected for multiple hypotheses, filtered to remove those with a corrected p-value > 0.01, and ranked
according to fold enrichment leaving 149 GO terms. Biological processes associated with neuronal
function are listed in Table 4.4.

Quantitative Reverse Transcription Polymerase Chain Reaction
Tet1, Tet2, and Tet3 expression of Hb9-puro embryonic stem cells, embryoid bodies, 2-/2+
embryoid bodies, and neural progenitor cells was determined by qRT-PCR using pre-validated TaqMan
probes (Life Technologies) (Figure 4.S5). RNA was extracted following the protocol mentioned above and
1.5 ml of cDNA was used to run Taq-Man qPCR reactions, using TaqMan® Universal Master Mix II,
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without UNG (cat no. 4440043, Life Technologies), plus commercially available TaqMan primers to Tet1
(Mm01169087_m1), Tet2 (Mm00524395_m1) and Tet3 (Mm00805756_m1) genes. All data were
normalized to the endogenous control 18S ribosomal RNA (Rn18S, Mm03928990_g1) (Life
Technologies) and quantitative measurements determined using the ΔΔCΤ approach.

DNA Methylation Datasets
Embryonic stem cell, neuronal progenitor cell, and astrocyte processed DNA methylation calls
were downloaded from NCBI Gene Expression Omnibus repository under accession numbers GSE30206
and GSE11034 (Meissner et al. 2008; Stadler et al. 2011).
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FIGURE 4.1

Figure 4.1 Schematic of in vitro differentiation protocol for creating pure motor neuron
populations. Embryonic stem cells are differentiated into embryoid bodies (EBs) in DFK5 media for two
days and further induced down the neural lineage with retinoic acid and sonic hedgehog agonist for four
days to form cell aggregates that express neural progenitor markers Olig2 and Hb9/MNR2. Neural
progenitor cells (NPCs) are dissociated and plated on poly-ornithine plates in DFK5 media containing
puromycin and neurotrophic factors. Twenty-four hours after selection (Day 0), media is replaced and
cells cultured for four days (Day 4). Gray boxes represents one day. See Materials and Methods for
additional culturing details.
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FIGURE 4.2

Figure 4.2 Immunocytochemistry of motor neurons after puromycin selection. Cultures were fixed
with paraformaldehyde and stained with class III β-tubulin (β-tubIII, recognized by Tuj1 antibody) at 24
hours (Day 0), two days (Day 2), or four days (Day 4) after puromycin selection to visualize neurite
growth.
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FIGURE 4.3
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Figure 4.3 Quantification of the morphological features of motor neurons over time. Motor neurons
exhibit the growth of processes from Day 0 to Day 4 as quantified by total networks (top left), cell area
(top right), number of neurite branching points (middle left), total length of neurites (middle right), and
number of total neurites (bottom). Each time point represents the average of five biological replicates.
Error bars show the standard error of the mean. * p-value < 0.05; ** p-value <0.01; ****p-value <0.001.
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FIGURE 4.4

Figure 4.4 Quantification of electrophysiological features of motor neurons over time. (Top row)
Whole-cell current density (pA/pF) was recorded of D0, D2, D4, and D6 motorneurons in response to
agonists for specific ligand-gate ion channels; K: AMPA/kainate, N: NMDA, Gly: glycine, and Gaba:
GABA receptors. (Bottom row) Left panel shows whole-cell capacitance (pF) of motor neurons at D0, D2,
D4, and D6 post-selection and the right panel shows whole-cell input resistance across D0, D2, D4, and
D6 time points.
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FIGURE 4.5

Figure 4.5 Motor neurons gain and lose DNA methylation with time. DNA methylation changes
between D0 and D4 motorneurons was assessed using a Fisher’s Exact Test. (Left panel) Dot plot of the
inverse log2 p-value as a function of percent methylation difference between D0 and D4 motor neurons.
CpGs passing Bonferonni multiple-hypothesis corrections with a percent methylation change of less than
-25 or greater than 25 were considered as hypomethylated (blue) and hypermethylated (yellow),
respectively. Horizontal dotted line represents the Bonferonni corrected p-value cutoff and the vertical
dotted lines show a -25 and 25 percent methylation difference cutoff. (Right panel) Unsupervised
hierarchical clustering heatmap of percent methylation for the 2,896 hypomethylated and the 1,153
hypermethylated CpGs in D0, D2, and D4 motor neurons. Each row represents an individual CpG. Yellow
denotes high (e.g. 100) percent methylation levels and blue denotes low (e.g. 0) percent methylation
levels at a particular time point.
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TABLE 4.1
GO	
  Term

Description

P-‐value

FDR	
  q-‐value Enrichment

GO:0097485 neuron	
  projection	
  guidance

5.77E-‐10

2.58E-‐07

3.05

GO:0007411 axon	
  guidance

5.77E-‐10

2.49E-‐07

3.05

GO:0001525 angiogenesis

1.06E-‐08

2.73E-‐06

2.54

GO:0010975 regulation	
  of	
  neuron	
  projection	
  development

3.18E-‐08

7.88E-‐06

2.27

GO:0045664 regulation	
  of	
  neuron	
  differentiation

1.04E-‐10

5.78E-‐08

2.2

GO:0051960 regulation	
  of	
  nervous	
  system	
  development

7.45E-‐13

9.64E-‐10

2.13

GO:0016477 cell	
  migration

2.62E-‐11

1.91E-‐08

2.13

GO:0031344 regulation	
  of	
  cell	
  projection	
  organization

3.70E-‐08

8.61E-‐06

2.13

GO:0050767 regulation	
  of	
  neurogenesis

1.77E-‐11

1.47E-‐08

2.12

GO:0051270 regulation	
  of	
  cellular	
  component	
  movement

8.85E-‐11

5.15E-‐08

2.09

GO:0048598 embryonic	
  morphogenesis

5.28E-‐11

2.56E-‐08

2.75

GO:0007389 pattern	
  specification	
  process

2.16E-‐08

4.57E-‐06

2.5

GO:0048731 system	
  development

4.49E-‐11

2.28E-‐08

2.37

GO:0045597 positive	
  regulation	
  of	
  cell	
  differentiation

5.12E-‐09

1.32E-‐06

2.27

GO:0051960 regulation	
  of	
  nervous	
  system	
  development

7.15E-‐09

1.66E-‐06

2.25

GO:0007275 multicellular	
  organismal	
  development

2.56E-‐14

9.94E-‐11

2.24

GO:0051094 positive	
  regulation	
  of	
  developmental	
  process

1.04E-‐10

4.64E-‐08

2.17

negative	
  regulation	
  of	
  transcription	
  from	
  RNA	
  polymerase	
  II	
  
GO:0000122 promoter

5.45E-‐08

9.91E-‐06

2.17

GO:0060284 regulation	
  of	
  cell	
  development

5.27E-‐08

9.74E-‐06

2.09

GO:0045892 negative	
  regulation	
  of	
  transcription,	
  DNA-‐dependent

1.78E-‐09

5.30E-‐07

2.04

Table 4.1 Gene Ontology (GO) enrichment analysis of the genes nearest to differentially
methylated CpGs. GO term p-values were adjusted for multiple hypothesis (FDR<5%) and ranked
according to enrichment. The top ten GO terms of genes associated with hypomethylated (upper) and
hypermethylated CpGs (lower) are shown.
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FIGURE 4.6

Figure 4.6 CpGs hypomethylated in motorneurons are hypermethylated in NPCs and astrocytes.
Unsupervised hierarchical clustering of the methylation status of hypomethylated CpGs in NPCs, D0
motor neurons, D2 motor neurons, D4 motor neurons, and astrocytes. The heatmap shows that 87% and
82% of hypomethylated CpGs are highly methylated (>=75%) in NPCs and astrocytes, respectively. The
colored bar in the lower portion represents the expected result for motor neuron-specific methylation loss.
Each row of the heatmap represents an individual CpG. Yellow denotes high (e.g. 100) percent
methylation levels and blue denotes low (e.g. 0) percent methylation levels.
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FIGURE 4.7

FIGURE 4.7 Gene expression profiling of neural progenitors and motor neurons. Microarray
hybridization was performed on RNA isolated from neural progenitor cells (NPC), day 0 motor neurons
(D0), day 2 motor neurons (D2), and day 4 motor neurons (D4). Genes differentially expressed between
D0 and D4 motor neurons were identified using Student’s t test and corrected for multiple hypothesis
using Benjamini & Hochberg’s (FDR) method. (Left panel) Dot plot of the inverse log2 p-value as a
function of the log2 ratio of D0 and D4 expression. Red dots represent statistically significant upregulated
probes and green dots represent statistically significant downregulated probes. Horizontal dotted line
represents the multiple hypothesis corrected significant cutoff (q-value<0.05). (Right panel) Unsupervised
hierarchical clustering heatmap of all probes differentially expressed between D0 and D4 motor neurons.
Red and green indicate low and high expression levels, respectively. (A.U.) Arbitrary Units. Each sample
represents the average of three biological replicates.
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TABLE 4.2
GO	
  Term

Description

P-‐value

FDR	
  q-‐value Enrichment

GO:0035235

ionotropic	
  glutamate	
  receptor	
  signaling	
  pathway

5.07E-‐06

4.91E-‐03

33.82

GO:0035249

synaptic	
  transmission,	
  glutamatergic

1.71E-‐05

1.04E-‐02

25.37

GO:0007215

glutamate	
  receptor	
  signaling	
  pathway

5.55E-‐05

2.80E-‐02

19.02

GO:0051966

regulation	
  of	
  synaptic	
  transmission,	
  glutamatergic

7.09E-‐05

3.05E-‐02

17.90

GO:0007270

neuron-‐neuron	
  synaptic	
  transmission

1.00E-‐05

7.28E-‐03

17.29

GO:0050905

neuromuscular	
  process

1.35E-‐05

8.69E-‐03

11.56

GO:0007268

synaptic	
  transmission

8.73E-‐10

1.01E-‐05

11.14

GO:0007267

cell-‐cell	
  signaling

1.65E-‐08

6.41E-‐05

7.64

GO:0044700

single	
  organism	
  signaling

7.35E-‐08

2.14E-‐04

6.73

GO:0023052

signaling

7.35E-‐08

1.71E-‐04

6.73

GO:0034645

negative	
  regulation	
  of	
  muscle	
  cell	
  apoptotic	
  process

2.24E-‐05

4.34E-‐02

54.17

GO:0009059

cellular	
  macromolecule	
  biosynthetic	
  process

3.02E-‐06

3.51E-‐02

3.43

GO:0044249

macromolecule	
  biosynthetic	
  process

3.93E-‐06

2.28E-‐02

3.36

GO:1901576

cellular	
  biosynthetic	
  process

7.35E-‐06

2.85E-‐02

2.91

GO:0009058

organic	
  substance	
  biosynthetic	
  process

1.09E-‐05

3.17E-‐02

2.83

GO:0010656

biosynthetic	
  process

1.51E-‐05

3.52E-‐02

2.77

Table 4.2 Gene Ontology enrichment of biological processes for genes differentially expressed
between D0 and D4 motorneurons. GO term p-values were adjusted for multiple hypotheses (FDR<5%)
and ranked according to enrichment. All GO categories that pass multiple hypothesis corrections are
shown for upregulated (top) and downregulated (bottom) genes.
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TABLE 4.3
GO	
  Term

Description

P-‐value

FDR	
  q-‐value Enrichment

GO:0005219 ryanodine-‐sensitive	
  calcium-‐release	
  channel	
  activity

4.28E-‐05

7.62E-‐03

152.19

GO:0048763 calcium-‐induced	
  calcium	
  release	
  activity

1.28E-‐04

2.09E-‐02

101.46

GO:0004971 alpha-‐amino-‐3-‐hydroxy-‐5-‐methyl-‐4-‐isoxazole	
  propionate	
  

2.55E-‐04

3.69E-‐02

76.1

GO:0005234 extracellular-‐glutamate-‐gated	
  ion	
  channel	
  activity

1.69E-‐06

4.41E-‐04

43.48

GO:0004970 ionotropic	
  glutamate	
  receptor	
  activity

2.30E-‐06

5.61E-‐04

40.58

GO:0008066 glutamate	
  receptor	
  activity

9.77E-‐06

2.25E-‐03

28.99

GO:0004890 GABA-‐A	
  receptor	
  activity

2.10E-‐04

3.29E-‐02

25.37

GO:0016917 GABA	
  receptor	
  activity

3.38E-‐04

4.72E-‐02

21.74

GO:0005230 extracellular	
  ligand-‐gated	
  ion	
  channel	
  activity

2.05E-‐07

6.16E-‐05

16.65

GO:0005231 excitatory	
  extracellular	
  ligand-‐gated	
  ion	
  channel	
  activity

2.15E-‐04

3.24E-‐02

13.53

glutamate	
  receptor	
  activity

Table 4.3 Gene Ontology enrichment analysis of functional categories for genes upregulated
between D0 and D4 motorneurons. GO term p-values were adjusted for multiple hypotheses (FDR<5%)
and ranked according to enrichment. The top ten GO terms of upregulated genes are shown.
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FIGURE 4.8

Figure 4.8 Differentially methylated CpGs are associated with differentially expressed genes. For
all differentially methylated CpGs, the expression level of the nearest gene was compared between D0
and D4 motorneurons. The plot shows the expression change relative to the difference in DNA
methylation between D0 and D4 motorneurons. Red dots represent upregulated genes and green dots
represent downregulated genes (p-value<0.05, Student’s t test).
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TABLE 4.4
GO	
  Term	
  
GO:48665	
  
GO:21522	
  
GO:21517	
  
GO:48663	
  
GO:21515	
  
GO:21510	
  
GO:30182	
  

Description	
  
neuron	
  fate	
  specification	
  
spinal	
  cord	
  motor	
  neuron	
  
differentiation	
  
ventral	
  spinal	
  cord	
  development	
  
neuron	
  fate	
  commitment	
  
cell	
  differentiation	
  in	
  spinal	
  cord	
  
spinal	
  cord	
  development	
  
neuron	
  differentiation	
  

GO:48699	
  

generation	
  of	
  neurons	
  

GO:22008	
  

neurogenesis	
  

Genes	
  
Isl1,	
  Lhx3,	
  Atoh1,	
  Foxa2	
  

P-‐value	
  
2.08E-‐07	
  

FDR	
  q-‐value	
  
2.52E-‐03	
  

Enrichment	
  
76.37	
  

Rank	
  
6	
  

Isl1,	
  Phox2a,	
  Lhx3,	
  Tbx20	
  
Isl1,	
  Phox2a,	
  Lhx3,	
  Tbx20	
  
Isl1,	
  Smad4,	
  Lhx3,	
  Atoh1,	
  Pax7,	
  Foxa2	
  
Isl1,	
  Phox2a,	
  Lhx3,	
  Pax7,	
  Tbx20	
  
Isl1,	
  Phox2a,	
  Lhx3,	
  Pbx3,	
  Pax7,	
  Tbx20	
  
Isl1,	
  Phox2a,	
  Smad4,	
  Pbx3,	
  Stat3,	
  
Pax7,	
  Mef2c,	
  Tbx20,	
  Foxa2,	
  Lhx2,	
  
Lhx3,	
  Atoh1	
  
Isl1,	
  Phox2a,	
  Smad4,	
  Pbx3,	
  Atf1,	
  
Stat3,	
  Pax7,	
  Mef2c,	
  Tbx20,	
  Foxa2,	
  
Lhx2,	
  Tcf3,	
  Lhx3,	
  Atoh1	
  
Isl1,	
  Phox2a,	
  Smad4,	
  Pbx3,	
  Atf1,	
  
Stat3,	
  Pax7,	
  Mef2c,	
  Tbx20,	
  Foxa2,	
  
Lhx2,	
  Tcf3,	
  Lhx3,	
  Atoh1	
  

4.61E-‐07	
  
7.48E-‐07	
  
1.01E-‐09	
  
2.90E-‐08	
  
2.53E-‐09	
  
5.96E-‐10	
  

5.58E-‐03	
  
9.04E-‐03	
  
1.22E-‐05	
  
3.50E-‐04	
  
3.06E-‐05	
  
7.21E-‐06	
  

63.01	
  
56.01	
  
55.59	
  
55.27	
  
47.85	
  
10.33	
  

7	
  
10	
  
11	
  
12	
  
13	
  
62	
  

3.81E-‐10	
  

4.60E-‐06	
  

8.04	
  

88	
  

8.26E-‐10	
  

9.99E-‐06	
  

7.58	
  

95	
  

Table 4.4 Gene Ontology (GO) enrichment analysis on transcription factors enriched for a
sequence motif in hypomethylated regions. We identified 149 statistically enriched GO terms (qvalue<0.01; FDR-adjusted) associated with hypomethylated regions and ranked them according to
enrichment fold. Table 4.4 presents those GO terms and TFs associated with neuronal function. No GO
terms were found to be enriched for hypermethylated regions.
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FIGURE 4.9

Figure 4.9 Motor neurons gain 5-hydroxymethylation with time. Puromycin-selected cultures were
fixed and stained with β-tubulin class III (β-tubIII) and an antibody targeting 5-hydroxymethylation (5hmC)
at 24 hours (Day 0), two days (Day 2), or four days (Day 4) after selection to visualize neurite growth and
the presence of 5hmC.
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FIGURE 4.10

Figure 4.10 Tet single knockout motor neurons show 5-hydroxymethylation. Puromycin-selected
cultures were fixed and stained with β-tubulin class III (β-tubIII) and an antibody targeting 5hydroxymethylation (5hmC) at 24 hours (Day 0), two days (Day 2), or four days (Day 4) after selection to
visualize neurite growth and the presence of 5hmC. Single knockout NPCs differentiate into normal motor
neurons that look morphologically normal through Day 4. Single knockout lines also show normal gains in
5hmC by Day 4.
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FIGURE 4.11

Figure 4.11 Tet double and triple knockout motor neurons show 5-hydroxymethylation. Unselected
cultures were fixed and stained with β-tubulin class III (β-tubIII) and an antibody targeting 5hydroxymethylation (5hmC) at 24 hours (Day 0), two days (Day 2), or four days (Day 4) after puromycin
selection to visualize neurite growth and the presence of 5hmC. Double knockout (DKO) and triple
knockout (TKO) show a significantly reduced ability to differentiate into motor neurons (MNs) as
demonstrated by the lower number of normal MNs at Day 0, Day 2, and Day 4. DKO and TKO MNs also
show 5hmC staining by Day 4 as demonstrated by the co-staining of β-tubulin class III (white) and 5hmC
(red). Cells not positive for β-tubulin class III, presumably glial precursors, showed significant 5hmC
staining in wildtype, DKO, and TKO cultures as shown by the large 5hmC positive areas (red). Note that
5hmC staining for DKO Day 0 failed.
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FIGURE 4.12

Figure 4.12 Model for active demethylation and gene activation. Our study finds motor neuronspecific transcription factor (TF) binding sites are actively demethylated during motor neuron
differentiation and maturation. These findings support a model in which regions that regulate motor
neuron-specific genes (e.g. Ret) contain TFs binding sites (e.g. Isl1) that are methylated in neuron
progenitor cells (1). During differentiation, Isl1 binds these regulatory regions and recruits the Tet
demethylation machinery, which removes the DNA methylation (2). Upon demethylation, the target gene
is activated (3).
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SUPPLEMENTARY FIGURES AND TABLES
FIGURE 4.S1

Figure 4.S1 Genomic distribution of differentially methylated CpGs. (Top panel) Background (left),
hypomethylated (middle), and hypermethylated (right) CpGs were classified as located in promoters,
exons, introns, or intergenic regions. (Bottom panel) Histogram of the distance to the nearest UCSC
defined transcription start site for background (left), hypomethylated (middle), and hypermethylated (right)
CpGs. Background, hypomethylated, and hypermethylated CpGs are located at a mean distance of 5,740
bp, 17,709 bp, and 14,262 bp from the nearest transcription start site (TSS), respectively.
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FIGURE 4.S2

Figure 4.S2 Hypomethylated CpGs and attendant gene expression. Unsupervised hierarchical
clustering was performed on the methylation status of hypomethylated CpGs across NPCs, D0, D2, and
D4 motorneurons (left). The absolute expression level of the gene nearest to the hypomethylated CpG is
plotted across NPCs, D0, D2, and D4 motorneurons (right). Yellow denotes high (e.g. 100) percent
methylation levels and blue denotes low (e.g. 0) percent methylation levels. Red and green indicate low
and high expression levels, respectively. (A.U.) Arbitrary Units. Each sample represents the average of
three biological replicates.
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FIGURE 4.S3

Figure 4.S3 Expression of transcription factors with enriched sequence motifs at hypomethylated
regions. Heatmap of the absolute expression level of each transcription factor across NPC, D0, D2, and
D4 timepoints. Rows are sorted on the ratio of NPC to D0 expression. Isl1, Pbx3, Stat3, and Smad4 show
a statistically significant increase in expression from NPC to D0 while Foxa2, Tbx20, Tcf3, Atf1, Phox2a,
and Lhx3 show a statistically significant decrease in expression. A.U.: arbitrary units.
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FIGURE 4.S4

Figure 4.S4 Absolute expression of Tet and Dnmt families across NPC, D0, D2, and D4. Expression
levels were determined by Affymetrix Mouse Gene 1.0 ST microarray. (A.U.) Arbitrary Units. * pvalue<0.05; *** p-value<0.005 (Student’s t test).
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Tet1 relative expression (a.u.)

2.0

Tet2 relative expression (a.u.)

2.0

Tet3 relative expression (a.u.)

FIGURE 4.S5
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Figure 4.S5 Wildtype expression of Tet1, Tet2, and Tet3 across various tissues. qRT-PCR analysis
of Tet expression in wildtype embryonic stem cells (ES), embryoid bodies (EB), EBs induced with retinoic
acid/shh agonist for two days (NPC (2-/2+)), EBs induced with retinoic acid/ssh agonist for four days
(NPC (2-/4+)), and various tissues. Values are normalized to ES expression. (a.u.); arbitrary units. ns, not
significant; ** p-value <0.01; *** p-value < 0.05; ****p-value <0.001.
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FIGURE 4.S6

Figure 4.S6 Sanger sequence validation of knockout alleles. A portion of the wildtype and knockout
Tet1, Tet2, or Tet3 allele is represented for either (A) Tet1, Tet2, or Tet3 single knockouts, (B) Tet1/Tet2
double knockout, or (C) Tet1/Tet2/Tet3 triple knockout.
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FIGURE 4.S7

Figure 4.S7 DNA methylation and expression of putative Isl1-regulated genes App and Ret. (Left
panel) DNA methylation heatmap of hypomethylated CpGs associated with App (1 CpG) and Ret (3
CpGs) were found to be enriched for the Isl1 sequence motif. All CpGs show significant loss of DNA
methylation by D4 after differentiation and are specific to motor neurons. (Right Panel) Heatmap of App
and Ret absolute expression across time shows App is activated upon differentiation (D0) while Ret is
gradually activated through D2 and D4 after differentiation. Yellow denotes high (e.g. 100) percent
methylation levels and blue denotes low (e.g. 0) percent methylation. White denotes missing data. Red
and green indicate low and high expression levels, respectively. (A.U.) Arbitrary Units. Each sample
represents the average of three biological replicates.
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TABLE 4.S1
https://cgs.wustl.edu/~maxim/Thesis/Chapter4/Table4.S1.xlsx
Table 4.S1 List of CpGs that show a statistically significant gain or loss of DNA methylation
between D0 and D4 motor neurons. The table contains the DNA methylation status and read coverage
for each CpG across embryonic stem cells, neural progenitor cells, D0 motor neurons, D2 motor neurons,
D4 motor neurons, and astrocytes as well as categorizes each CpG as changing early (from D0 to D2) or
late (from D2 to D4). The URL address above contains a link to Table 4.S1.

TABLE 4.S2
https://cgs.wustl.edu/~maxim/Thesis/Chapter4/Table4.S2.xlsx
Table 4.S2 List of differentially expressed probes. The table contains a tab with normalized
expression levels of all probes (“Expression_Master”), a tab listing the probes that are differentially
expressed between NPCs and D0 motor neurons (“NPCvD0”), a tab listing the probes that are
differentially expressed between D0 and D4 motor neurons (“D0vD4”), a tab listing probes downregulated
from D0 to D4 motor neurons, and a tab listing probes upregulated from D0 to D4 motor neurons. The
URL address above contains a link to Table 4.S2.

TABLE 4.S3
https://cgs.wustl.edu/~maxim/Thesis/Chapter4/Table4.S3.xlsx
Table 4.S3 List of CpGs that show a statistically significant gain of DNA methylation and are
associated with genes that increase in expression and CpGs that show a statistically significant
loss of DNA methylation and are associated with genes that decrease in expression between D0
and D4 motorneurons. The table contains the DNA methylation status and expression of its associated
gene of ES cells, NPCs, D0 motor neurons, D2 motor neurons, and D4 motor neurons. The URL address
above contains a link to Table 4.S3.
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CHAPTER 5: CONCLUDING REMARKS AND DISCUSSION

The onset of next-generation massively paralleled sequencing as a commoditized tool has
significantly advanced our understanding of the role of DNA methylation in normal development, health,
and disease. Before the start of this thesis, whole genome or genome-wide methylation maps were nonexistent. Researchers dissected the methylation patterns of single loci under various conditions or in
various cell states. Currently, whole genome patterns of 5-methylcytosine (5mC) is being catalogued
across human tissues and disease states. What’s more, within the past five years the field has
established the importance of 5-hydroxymethylcytosine (5hmC), a novel genomic mark, in early
development and has elucidated several mechanisms of active DNA demethylation. We now have a more
complete understanding of the factors involved in establishing, maintaining, reading, and erasing DNA
methylation. Several questions (among many) are still outstanding in the field.

What is the informative unit of DNA methylation?
A question that has always been at the forefront of the DNA methylation field is whether individual
CpGs or multiple CpGs together account for functional regulation. In other words, can each individual
CpG inform biology or does a region have to reach a methylation threshold to effect its role in a cell? Until
recently, Differentially Methylated Regions (DMRs) and the average methylation status of all CpGs within
a CpG Island (CGI), were thought to be the only informative unit for transcriptional regulation. The high
density of CpGs within 200-500 base pair CGIs alluded to a mechanism in which the absolute level of
CpG methylation across the entire region dictated gene regulation. Furthermore, because CGIs are
enriched at gene promoters, the natural inclination has been to ascribe the CGI unit with a regulatory
function controlled by CpG methylation. The focus on CGIs is an unintended consequence of the
introduction of genome sequencing and the desire to interrogate as many CpG dinucleotides as possible
relative to experimental costs. Naturally, focusing on has CGIs allowed for a fairly comprehensive,
genome-wide evaluation but biased the field toward interrogating promoter methylation. Covariance
analysis of the methylation status of CpGs and their nearest neighborhoods has strengthened the notion
that the CpGs within large genome regions have a similar methylation status. These studies have shown
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that if a CpG is highly methylated, the probability is high that its nearest neighbor is also methylated.
Furthermore, many studies have shown that entire CGIs can show differential methylation between
normal cell types and that cancer, in particular, loses methylation boundaries which results in large,
megabase blocks of hypomethylated regions. The methylation profiling of adrenocortical neoplasias
featured in this thesis, also demonstrates that larger regions, namely CGIs, can exhibit large methylation
changes in disease models.
On the other hand, many examples abound from the 1980s and 1990s showing that the
methylation status of an individual CpG is sufficient to disrupt the binding of transcription factors or to
recruit methyl-binding proteins. Although the entire region could often not be analyzed, it is now clear that
individual CpGs can affect transcription. The DNA-binding factor CTCF insulates the effects of distal
enhancers from promoters to regulate expression and contains multiple potential CpG sites within its
binding motif. The methylation of one of these CpG sites prevents DNA binding and gene repression. The
methylation of a single CpG can also recruit proteins with methyl-binding domains. Their binding to
methylated DNA recruits histone modifying proteins to establish repressive chromatin states. My study on
the changing methylation landscape of maturing motor neurons provides evidence for both models
suggesting individual CpGs can be informative and that the DNA methylation state of a cluster of CpGs
confers biological information. Many of the CpGs I observed to gain or lose methylation between D0 and
D4 motor neurons were the only differentially methylated CpG associated with a gene. The dramatic
change in methylation observed (>25%) as well as the importance of many of the nearest genes suggests
these CpGs are biologically important and play a regulatory role. Many other differentially methylated
CpGs, however, were located within 200 base pairs of each other (clustered). Most often, these CpGs all
showed a change in methylation status in the same direction though some instances were observed in
which one CpG gained methylation and its nearest neighbor lost methylation. The former case supports
the idea that large genomic regions are the informative unit while the later case suggests each CpG plays
a unique role. Why nearby CpGs would both gain and lose methylation, however, is yet to be determined.
From my studies, it is evident that single CpG and multi-CpG methylation changes occur and both are
most likely biologically relevant.

120

Why does CpG methylation not correlate with expression on the global level?
The first studies of the functional role of DNA methylation definitively showed that methylation is
associated with a transcriptionally repressive state. We have since come to better understand the
dynamic interplay between chromatin state and DNA methylation state, but still are unable to predict
transcriptional expression based on DNA methylation. What’s more, global methylome and transcriptome
studies show very poor correlation between DNA methylation and expression. The poor overall
correlation could be due to several reason, all of which reflect a gap in our understanding and represent
unique opportunities for future discovery.
One explanation for the poor correlation between methylation and expression could simply be
due to our limited knowledge of the information content of each CpG. In other words, we still are unsure
which CpGs regulate which genes. 3D chromatin mapping experiments have shown that the genome
forms complex physical interactions between distal genomic regions. For example, enhancers have been
shown to interact with gene prompters tens of thousands of kilobases away. Similarly, proximal CpGs
may not provide the most predictive power for determining expression. The genomic description of the
differentially methylated CpGs identified in my study of maturing motor neurons (Figure 4.S1) shows that
most methylation changes occur 10-15 kilobases from transcription start sites (TSSs). Most putative
enhancers are also found at roughly the same distance from TSSs as these differentially methylated
CpGs. As more whole genome datasets across multiple cell types become available, correlations can be
made between the methylation status of every CpG and the expression level of every gene to identify
regulatory CpGs.
Moreover, the biologically significance of methylation levels further confounds our interpretation of
DNA methylation and precludes correlative studies. In theory, because of the binary nature of DNA
methylation, the methylation of a CpG within one cell can exist in only one of three states: 100%
methylated (both alleles methylated), 50% methylated (one allele methylated, one allele unmethylated), or
0% methylated (both alleles unmethylated). Empirically, CpG methylation is bimodally distributed between
fully methylated (100%) and fully unmethylated (0%) states. Imprinted loci that are 50% methylated are
the exception. Furthermore, intermediate methylation states, percent methylation that is not 0, 50, or
100%, are also observed. The observation of intermediate methylation states (e.g. 30% or 70%) could
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mean the presence of technical artifacts. Since all studies to date are not single cell and, therefore
percent methylation of a CpG is the average methylation of all alleles in all cells, the observation of
intermediate methylation most likely suggests the CpG methylation state varies among cells. The lack of
correlation between methylation and expression could, therefore, be due to the fact that methylation is a
binary variable while gene expression is a discrete variable. Single-cell transcription and methylation
mapping experiments are necessary to more accurately describe the relationship between individual CpG
methylation and gene expression.

What is the role of CpH methylation?
The methylation of cytosine outside of the CpG context was first demonstrated to occur in
embryonic stem (ES) cells and subsequently lost upon differentiation. Recently, the presence of CpH
(H=A, C, or T) methylation was discovered in the mammalian brain. CpH methylation occurs primarily
within the gene body, whereas CpG methylation is distributed across the genome. Like methylation at
CpGs, CpH methylation in the brain is negatively correlated to gene transcript abundance. In ES cells
however, CpH methylation is positively correlated to gene transcript abundance.
The key to understanding the role of CpH methylation may lie in its asymmetry. Because the
CpA, CpC, and CpT nucleotide pairs do not contain a cytosine on its opposite strand, methylation can
only occur on one strand. When a cell with CpH methylation divides, one cell could inherit the hemimethylated chromosome pairs while another cell could inherit the completely unmethylated
chromosomes, effectively erasing the CpH methylation. Stem cells are known to undergo obligatory
asymmetrical replication in which one pluripotent or multipotent cell divides into one mother cell that is
identical to the original stem cell and into one daughter cell that is differentiated. The asymmetric division
of CpH methylation may be a marker for stemness and instruct the dividing cell to remain in the
pluripotent or multipotent state. The daughter cell that receives the unmethylated DNA strands would be
signaled to differentiate due to the lack of CpH methylation. Experiments that can specifically disrupt CpH
methylation in ES cells or synthetically introduce CpH methyl marks are necessary to test this hypothesis
and elucidate CpH function.
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How is DNA methylation directed?
Although we have a thorough understanding of the methyltransferase machinery, we have yet to
determine how DNA methylation is directed to specific genomic sequences. Dnmt1 is primarily
responsible for maintaining DNA methylation states through cell divisions by faithfully adding a methyl
group to the cytosines of hemi-methylated, recently replicated, DNA. Dnmt3b is active early in
development where it adds methyl groups to completely unmethylated pericentric regions and some
repetitive elements. Dnmt3a more broadly methylates DNA across various genomic features throughout
development and in adult tissues. Dnmt3l confers some specificity to direct Dnmt3a to imprinted loci and
repetitive elements. The general specificity of each of the de novo methyltransferases can be explained
by differences in their DNA binding domains or interaction with Dnmt3l, but factors that determine cell
type-specific deposition of methyl groups is still unclear.
An important question underlying how DNA methylation status is determined is to understand
what is the default methylation state of DNA: is the natural tendency of the methyltransferase machinery
to methylate all cytosines with some sequences excluding the Dnmts or is the default state of the cell to
be unmethylated with Dnmts directed to specific sequences by chaperones or cofactors? This question is
further complicated when considering the process of cell division and the process of passive versus
active demethylation. Studies have shown that Sp1 is associated with unmethylated sequences,
especially CGIs. The additional of Sp1 binding sites to DNA that is methylated results in the prevention
(or loss) of methylation while the mutation of Sp1 binding sites in unmethylated DNA results in gains of
methylation within that region. Experiments with the Epstein-Barr virus suggest that binding of
transcription factors alone is sufficient to prevent methylation of DNA in the case of replication-dependent
mechanisms. These studies suggest a model where DNA-binding factors exclude the methyltransferase
machinery from binding and methylating DNA.
Studies of the Oct4 and p15 promoters, however, suggest a different model in which specific
factors direct the addition of methylation at unmethylated regions. In this case, the Oct4 promoter
acquires methylation upon differentiation. The methylation state in differentiated cells results from the
binding of G9A and subsequent recruitment of DNMT3A and DNMT3B to the Oct4 promoter.
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Aberrant methylation gains in cancer can also teach us about the default state of DNA. p15, a
tumor-suppressor genes, is highly methylated in the breast cancer cell line, MCF7. This methylation
seems to be due to DNMT3A and mediated by ZNF217. Knockdown of ZNF217 by siRNA results in
complete loss of methylation at the p15 promoter suggesting that ZNF217 directs the methylation at the
p15 promoter by recruiting DNMT3A.
Most likely, depending on the cellular context, both models described occur. My work in mapping
methylation in maturing motor neuron suggests that specific factors can direct the removal and additional
of DNA methylation at specific loci in an active, non-replication-dependent manner.
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